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ABSTRACT 
SARA R. JACOBS: Multilevel Predictors of Cancer Clinical Trial Enrollment among 
CCOP Physicians  
(Under the direction of Bryan J. Weiner)  
 
Despite the potential benefits, only 3-5% of American adults with cancer 
participate in cancer clinical trials. One intervention aimed at increasing participation in 
clinical trials is the Community Clinical Oncology Program (CCOP), a cancer focused 
provider-based research network administered by the National Cancer Institute (NCI).  
Although drivers of enrollment at the CCOP level are well understood, no research has 
exclusively examined enrollment among CCOP physicians.  
The objective of this dissertation was to understand the factors that predict 
enrollment of patients in NCI-sponsored cancer clinical trials among CCOP physicians. 
Data were obtained from the 2011 Annual CCOP Progress Reports, two surveys 
conducted in 2011 among CCOP administrators and physicians, and the 2012 
American Medical Association Physician Masterfile. The sample consisted of 485 
CCOP physicians.  We used structural equation modeling to analyze three models that 
predicted physician enrollment.  
Our first analysis sought to determine the physician characteristics, attitudes, and 
CCOP factors associated with physician enrollment. Our results demonstrated that 
physicians’ attitudes toward participating in CCOP, and CCOP policies and practices 
(e.g. trainings offered, expectations instituted, support provided) were both significant in 
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directly predicting enrollment, although neither physician characteristics nor CCOP 
factors were indirectly associated with enrollment operating through physician attitudes. 
In the second analysis, we included physicians’ perceptions of CCOP, and tested 
whether fit between CCOP and physicians’ values moderated the effect of physicians’ 
perceptions of implementation climate (i.e., a climate that supports, rewards, and 
expects implementation) on enrollment. Our results demonstrated that both constructs 
were significantly associated with enrollment and including the moderator improved 
overall fit of the model. Lastly, we included both CCOP factors and perceptions of 
context in a single model. Our results confirmed that implementation climate mediated 
the relationship between organizational policies and practices and enrollment 
Overall, the results have both theoretical and practice implications. This 
dissertation extends the setting and unit of analysis in which innovation implementation 
theories have been tested. In addition, the findings from this dissertation could be used 
to develop physician directed strategies aimed at increasing involvement in clinical 
research. These strategies will be increasingly important as the CCOP network 
continues to evolve.  
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CHAPTER 1: INTRODUCTION  
 
Cancer clinical trials are instrumental in the development of innovative cancer 
treatments as well as in the expansion of current diagnostic, control, and prevention 
techniques. Evidence demonstrates that cancer clinical trials have the potential to not 
only improve health outcomes for participating patients, but may also increase the 
quality of cancer care more generally by facilitating translation of research discoveries 
into clinical practice (Sorbye et al., 2009) (Grunfeld et al., 2002).  Despite the potential 
for positive health outcomes, only 3-5% of adults with cancer in the United States 
actually participate in a cancer clinical trial (NCI Cancer Bulletin, 2010). In an effort to 
improve enrollment among all cancer patients, there has been an increasing interest in 
developing specific interventions to enhance patient participation in cancer clinical trials.   
 Patients can typically enroll in four types of cancer clinical trials. Cancer treatment 
trials test the efficacy and safety of new therapies. Cancer prevention trials test new 
interventions aimed at lowering the risk of developing cancer. Cancer prevention trials 
may include people who have a higher than average risk of developing cancer or are 
cancer survivors. Cancer screening and diagnostic clinical trials test new ways of 
detecting and/or diagnosing cancer earlier and more accurately. Screening trials often 
include patients with no signs of cancer while diagnostic trials often include people who 
have some signs or symptoms of cancer. Lastly, cancer quality of life or symptom 
management trials focus on providing comfort and improving the quality of life for 
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cancer patients and/or cancer survivors. Clinical trials can be sponsored by government 
agencies such as the National Cancer Institute (NCI) or the Veterans Health 
Administration, but they can also be sponsored by other organizations such as 
foundations, biotechnology and pharmaceutical companies, or academic medical 
centers (NCI, 2010).  
 One intervention aimed at increasing patient participation in NCI-sponsored clinical 
trials is the Community Clinical Oncology Program (CCOP), a cancer-focused provider-
based research network administered by NCI. The goal of the CCOP network is to 
engage community physicians in NCI-sponsored clinical trials in order to enhance the 
incorporation of research results into practice (NCI, 2010).  The CCOP network is a joint 
venture between NCI, clinical cooperative groups or research bases (which design and 
develop specific clinical trial protocols), and community-based physicians and hospitals 
(Kaluzny et al., 1994).  The CCOP network is administered by NCI’s Division of Cancer 
Prevention, which provides overall direction and funding for community hospitals and 
physicians to participate in clinical trials. The CCOP clinical cooperative groups support 
the design and execution of clinical trials, and the individual community-based 
physicians and hospitals assist with patient enrollment, data collection, and 
dissemination of study findings (Kaluzny et al., 1994) (Minasian et al., 2010).  
 Since its inception in 1983, the CCOP network overall has provided over 50% of 
the enrollment in NCI-sponsored cancer prevention and control trials and 30% of the 
enrollment in NCI-sponsored cancer treatment trials (Minasian et al., 2010).  Although 
the CCOP network has clearly been successful in increasing overall cancer clinical trial 
enrollment, participating physicians vary in their individual enrollment of patients 
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in cancer clinical trials.  It is well known that context is an important determinant of 
both organizational and individual behavior or performance (Kozlowski & Klein, 2000). 
Research to date has sought to identify the organizational and environmental contextual 
factors that drive patient clinical trial enrollment at the CCOP level (Kaluzny et al., 1995) 
(Carpenter et al., 2012) (Weiner et al., 2012) (Jacobs et al., 2013). However, no 
research has examined the individual physician characteristics and organizational 
contextual factors that predict CCOP physician success in enrolling patients in trials. 
Thus, there is a critical need to determine the context within which we can increase 
physician enrollment of cancer patients in cancer clinical trials. Context can be included 
in a study in three different ways. First, by including objective measures of context in a 
model that predicts individual performance. Second, by examining the role of 
perceptions of context in predicting behavior, and lastly by including both objective and 
perceived organizational context in a single model. In this dissertation, we examined 
these three ways to include organizational context.  The first aim examined the impact 
of objectively measured organizational factors on physician enrollment of patients while 
the second aim explored the relationship between physicians’ perceptions of context 
and enrollment. Lastly, the third aim expanded upon the work completed in the first two 
aims and examined both objective assessment of context and perceptions of context. In 
this setting, the data used were nested. For example, we examined individual CCOP-
affiliated physicians who practiced in a CCOP organization. This dissertation does not 
include organizational contextual factors at the hospital or clinic level as many of the 
physicians that participate in CCOP practice at multiple locations. In addition, patient 
accrual is attributed to the individual physician or CCOP organization rather than to the 
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hospital or clinic. 
 The overall research question was to understand the role of physician 
characteristics and organizational context in predicting the enrollment of patients 
in NCI-sponsored cancer clinical trials among CCOP-affiliated physicians. The 
central hypothesis was that organizational contextual factors and physician 
characteristics would directly and indirectly determine physician performance. This 
central hypothesis was tested in three separate aims. 
• Aim 1: To determine the physician characteristics and objective assessments of 
organizational context associated with higher enrollment of patients in NCI-
sponsored cancer clinical trials. 
 
• Aim 2: To examine the physician characteristics and physicians’ perceptions of 
organizational context associated with higher enrollment of patients in NCI-
sponsored cancer clinical trials. 
 
• Aim 3: To evaluate the objective assessments of organizational context and 
physicians’ perceptions of organizational context associated with higher 
enrollment of patients in NCI-sponsored cancer clinical trials. 
 
This dissertation utilized data from four sources: 1) 2011 Annual CCOP Progress 
Reports; 2) 2011 CCOP Administrator Survey; 3) 2011 CCOP-Affiliated Physician 
Survey; and 4) 2012 AMA Physician Masterfile. The CCOP Progress Reports provide 
information on each CCOP’s research and enrollment activities for the previous nine 
months and were primarily used to determine the dependent variable, patient 
enrollment, for all three aims. This dissertation utilized the 2011 Progress Reports 
submitted in March 2012, which cover the period from June 2011 to February 2012. The 
2011 Progress Reports overlap in timing with the 2011 CCOP Administrator and CCOP-
Affiliated Physician Surveys. The goal of CCOP Administrator Survey and Physician 
Survey were to learn more about how the CCOPs are organized and how they operate 
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as well as to better understand physician participation in the CCOP network. The CCOP 
Administrator Survey was primarily used for the objective assessments of organizational 
context in Aims 1 and 3 while the Physician Survey was used to determine physicians’ 
attitudes (Aim 1) and perceptions of organizational context for Aims 2 and 3. The 
physicians who responded to the physician survey (n=485) comprised the sample for all 
three aims. Lastly, AMA data were used to determine the physician characteristics 
included in all three aims.  
 The analytical approach for all three aims was structural equation modeling (SEM). 
SEM is advantageous as it allows researchers to test latent constructs that are not 
directly assessed, but rather are composed of observed data (e.g., organizational 
context, implementation climate, innovation-values fit). Second, SEM also takes into 
account measurement error by including error variables in the error portions of the 
observed variables; therefore conclusions about relationships are not biased by any 
measurement error. Lastly, SEM allows researchers to test complex frameworks that 
include mediation and moderation in a single model (Werner & Schermelleh-Engel, 
2009).  
 Determining the multilevel predictors of CCOP-affiliated physician success in 
enrolling patients in cancer clinical trials has significant policy and scientific implications. 
This dissertation contributes to the current knowledge base by identifying both individual 
physician characteristics and organizational contextual factors that predict CCOP-
affiliated physician enrollment of patients in cancer clinical trials. This contribution is 
both innovative and significant for its potential to be used as the foundation for 
strategies that promote physician enrollment of patients in cancer clinical trials as well 
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as physician adoption of innovations more generally. These findings are particularly 
important as NCI builds upon the success of the CCOP program and replaces both 
CCOP and the NCI Community Cancer Centers Program (NCCCP) with the NCI 
Community Oncology Research Program (NCORP). In addition, this dissertation also 
examined all three ways organizational context can be incorporated into models that 
predict individual behavior. By using models traditionally examined in management and 
information systems, we extended the settings in which innovation implementation 
theories may be applicable. In addition, we provided evidence for adapting these 
theories to examine individual level innovation implementation.   
 The dissertation is organized as follows: Chapter 2 discusses the current 
literature regarding barriers to cancer clinical trial enrollment, the success of the CCOP 
program, known physician predictors of patient enrollment in cancer clinical trials, 
methods to incorporate organizational context into models that predict individual 
behavior, and current innovation implementation frameworks. Chapter 3 provides an 
overview of the methods used throughout the dissertation. It includes a discussion of 
study design and rationale, hypotheses, data sources, study sample, and analytical 
approaches. Chapters 4-6 are manuscripts corresponding to Aims 1-3, respectively, and 
are intended for submission for peer-reviewed publication. Chapter 7 reviews the study 
findings, summarizes the implications for policy, practice, and research, discusses the 
limitations of this dissertation, and concludes with a discussion of future research. 
Tables and figures are provided at the end of each chapter. References are provided in 
a comprehensive bibliography at the conclusion of the dissertation. 
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CHAPTER 2: LITERATURE REVIEW 
 
Overview of Barriers to Clinical Trial Enrollment  
 
 As discussed, studies estimate that only 3-5% of adults with cancer participate in 
cancer-related clinical trials (NCI Cancer Bulletin, 2010). Specific enrollment in NCI-
sponsored breast, colorectal, lung, and prostate cancer clinical trials has been shown to 
be as a little as 1.8% among adults with these types of cancer. Enrollment tends to be 
lowest among racial and ethnic minorities, women, and the elderly (Murthy et al., 2004). 
Research demonstrates that barriers to successful patient enrollment occur at the 
patient, physician, and organizational levels (Winn, 1994). Despite evidence that cancer 
survivors are receptive to participating in a cancer clinical trial if their physician asked 
them to do so, some patients are still reluctant to enroll (Comis et al., 2003) (Comis et 
al., 2009). Patients may have concerns over the cost and/or coverage of the trial or lack 
transportation to the trial site (Mills et al., 2006). In addition, some patients report 
discomfort with the allocation of treatment component of cancer clinical trials and/or a 
lack of knowledge regarding what is required of a trial participant (Mills et al., 2006) 
(Ellis, 2000). For example, one study found that only 13% of survey respondents 
reported having a clear understanding of the term “clinical trial” and 29% reported 
having “not much idea” (Comis et al., 2009). Patients may also prefer to be more 
involved in the clinical decision-making process; or, they may fear and/or distrust the 
medical profession, specific research or researchers involved (Mills et al., 2006) (Ellis, 
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2000). For example, 40% of patients of who were aware of a clinical trial, but declined to 
participate, noted they were concerned that the new treatment might not be as effective 
as the standard treatment (Comis et al., 2009).  
  Physician-level barriers include concerns over the potential effect on the 
physician-patient relationship, as well as attitude towards and knowledge of the clinical 
trials themselves (Winn, 1994).  For example, some physicians may be concerned that 
they may lose contact with and control over the care of their patients once they enroll in 
clinical trials (Mansour et al., 1994). In addition, some physicians may not be aware of 
all the available trials and trial eligibility requirements for patients; they may also lack the 
time it takes to understand the nuances of the trial and follow-up with patients regarding 
the details of the specific protocol (Mansour et al., 1994). For example, in one study 
physicians immediately did not even consider a clinical trial for 38% of patients with 
cancer.  The primary reason stated was no available protocol.  Although the authors did 
confirm that for a small portion of patients no protocol was available, physicians were 
excluding patients even before reviewing what trials were available and the associated 
eligibility criteria.  The authors believed that these physicians lacked the appropriate 
knowledge of open trials and were not even considering clinical trials for patients based 
on misconceptions of ideal eligible patients (Lara et al., 2001).  Another important 
barrier to clinical trial enrollment are physician biases that the trial therapy is not as 
good as the standard therapy.  Although rarely if ever is the trial therapy not as good as 
the standard therapy, some physicians may be biased to think so (Mansour et al., 
1994).   
 At the organizational level, potential barriers include limited resources dedicated 
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to supporting cancer clinical trials, including the lack of support staff to help consent and 
enroll eligible patients (Shea et al., 1992). Other organizational barriers include having a 
limited number of trials available for physicians to enroll patients (Jacobs et al., 2013) 
(Weiner et al., 2012). Physicians also note that their organization could help facilitate 
patient enrollment by providing a synopsis of all open trials available at the point of care, 
simplifying enrollment forms, individualizing forms for each trial with specific information 
regarding specific tests, chemotherapy dose, and hiring additional trained staff to not 
only assist physicians with consenting and enrolling patients, but in the decision making 
process as well to help determine the appropriateness of a clinical trial for a patient 
(Fisher et al., 1991). Thus, successful interventions should try to alleviate barriers at the 
patient, physician, and organizational levels in order to increase the number of adults 
with cancer that enroll in a clinical trial.  
Success of the CCOP Network 
 The CCOP started in 1983 with the goal of engaging community physicians in 
NCI-sponsored clinical trials to improve the incorporation of clinical research results into 
practice. The program is complemented by the Minority-Based CCOP network (MB-
CCOP), which began in 1990 as a means to provide the infrastructure for clinical trials 
in those institutions, which serve communities with large minority and underserved 
populations (NCI, 2011). The CCOP and MB-CCOP network are administered by NCI’s 
Division of Cancer Prevention, which provides overall direction and funding for 
community hospitals and physicians to participate in clinical trials. In addition, there are 
CCOP sites that enroll patients into NCI-approved cancer clinical trials. A CCOP site 
can be a single community organization or a consortium of local hospitals and private 
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practices. A MB-CCOP site must meet the same requirements as the CCOPs, but must 
also have a population that is at least 40% minority or underserved. In addition, 
academic institutions are permitted to be MB-CCOPs, whereas they may not serve as 
the lead organization for a CCOP. The CCOP and MB-CCOP sites also affiliate with 
Research Bases, which design and develop the specific clinical trial protocols. Each site 
may affiliate with multiple Research Bases (NCI, 2011).  When the data were collected 
in 2011, there were 47 CCOPs across 28 states. The CCOPs included over 450 
hospitals and physician practices, with the average CCOP comprised of about 10 
hospitals and/or practice sites. CCOPs also included over 3,500 physicians, with the 
average CCOP composed of 48 physicians. Patient accrual to clinical trials is counted 
at the CCOP organizational level and at the individual physician level. CCOPs overall 
are required to enroll at least 100 patients per year across all types NCI-sponsored 
clinical trials (NCI, 2011). There is no current formal NCI requirement for individual 
physicians to enroll a minimum number of patients per year, although some CCOPs 
have instituted their own expectations for enrollment.  
 Physicians practicing at MB-COOPs were not analyzed in this dissertation as 
MB-CCOP affiliated physicians were included in the 2011 Physician Survey due to 
organizational differences between MB-CCOPs and CCOPs. As mentioned, academic 
medical centers are often the main site for MB-CCOPs. In addition, MB-CCOPs tend to 
be located in more urban areas as they are focused on enrolling minority and 
underserved patients. As expected the patient population seen at MB-CCOPs differ 
than those seen at CCOPs.  
 CCOP enrollment of adults and children with cancer provide over 30% of the 
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enrollment in NCI-sponsored cancer treatment trials and 50% of the enrollment in NCI-
sponsored cancer prevention and symptom management trials (Minasian et al., 2010).  
The program was been successful due to its ability to address barriers among patients, 
providers, and practices. The CCOP network not only provides organizational resources 
and support for physicians to enroll patients, it also allows patients to enroll in clinical 
trials in their community, at their local hospital or physician’s office, or where they most 
often seek care.   
To date, research has focused on identifying the organizational and 
environmental contextual factors that explain why programs are successful at the CCOP 
organizational level. Significant organizational contextual factors include the number 
and type of locations where patients can enroll, the number of research base affiliations, 
the number of hours per week worked by data managers, the number of active CCOP 
physicians, the number of open trials, the number of support staff, policies that 
recognize high accruing physicians, and the volume of new cancer patients (Kaluzny et 
al., 1995) (Carpenter et al., 2012) (Weiner et al., 2012) (Jacobs et al., 2013).  Key 
environmental contextual factors that predict CCOP level enrollment includes managed 
care penetration, hospital competition, and number of medical school affiliated hospitals 
in regions where CCOPs operate (Carpenter et al., 2006) (Carpenter et al., 2012). No 
current efforts, however, have examined the drivers of individual physicians’ enrollment 
of patients in cancer clinical trials among CCOP physicians.  
Physician Predictors of Clinical Trial Enrollment  
As discussed, no studies have examined the physician characteristics associated 
with clinical trial enrollment exclusively among CCOP physicians. Several studies have, 
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however, examined physician characteristics that are generally associated with clinical 
trial participation.  Physician characteristics associated with increased cancer clinical 
trial participation include medical specialty (i.e., medical oncologists compared to 
radiation oncologists), practice type (i.e., office-based practice compared to hospital 
based practice), prior participation in clinical trials, number of newly diagnosed patients 
seen, time spent with newly diagnosed cancer patients, training medical students or 
residents, and weekly tumor board participation (Klabunde et al., 2011).  Research also 
demonstrates that foreign-trained oncologists and oncologists who had participated in 
either pharmaceutical company sponsored trials or cooperative group sponsored trials, 
compared to those that participated in both types of trials tend to refer less patients to 
cancer clinical trials. In addition, physician age, race, and gender were generally not 
associated with cancer clinical trial participation (Klabunde et al., 2011) (Meropol et al., 
2007).   
Physician knowledge and attitudes also influence patient enrollment. For 
example, oncologists’ attitudes towards the value and importance of clinical trials 
directly influences whether a patient enrolls in a trial (Mansour et al., 1994).  One study 
found that when physicians offered a cancer clinical trial to their patients and their 
patients understood that they were being offered a trial, 75% of patients agreed to enroll 
(Albrecht et al., 2008). Therefore, physicians are instrumental in the enrollment process 
as they are the conduit between the healthcare organization and the patient.  Ultimately 
if a physician does not recommend a clinical trial to a cancer patient, it is extremely 
unlikely that that patient will enroll in a cancer clinical trial.  
Although these studies provide some initial insight into what physician 
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characteristics may drive patient enrollment in cancer clinical trials, notably, none of 
these studies were conducted exclusively among CCOP-affiliated physicians nor do 
they include organizational contextual factors in their analyses.  Physician 
characteristics that influence patient enrollment in cancer clinical trials may also differ 
among CCOP-affiliated physicians because they elect to participate in CCOP and 
therefore receive resource support from NCI to assist with screening and enrolling of 
eligible patients. Given that the mission of the CCOP network is to facilitate cancer 
clinical trial participation in local communities, CCOP-affiliated physicians may have a 
greater level of support and interest in encouraging their patients to enroll. Although, 
they may be different from other oncologists, there is still considerable variation among 
CCOP-affiliated physicians in their enrollment of patients. For example, in 2011, 
approximately 40% of CCOP physicians enrolled no patients (mean: 3; range: 0-88). 
Variation in physician enrollment has been observed in the program since its inception, 
yet no studies have systematically examined the reasons why this variation may occur. 
Therefore this research fills a necessary gap in the current knowledge base by 
evaluating the predictors of CCOP physicians’ enrollment of patients in NCI-sponsored 
cancer clinical trials.  
Incorporating Organizational Context in Research  
 
 Current research indicates that both individual-level characteristics and 
organizational context influence individual behavior (Kozlowski & Klein, 2000). For 
example, factors that predict CCOP physician enrollment of patients in trials likely 
occurs both at the individual physician level (e.g., medical specialty, values, attitudes) 
as well as at the CCOP level (e.g., organizational size, organizational policies that 
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incentivize enrollment, minimum accrual expectations). To comprehensively assess the 
determinants of physician enrollment, this dissertation incorporated factors at both 
levels. Including individual characteristics in an analysis is relatively straightforward, 
organizational context, however, can be incorporated in multiple ways.   
 The first approach examines either objective measures of organizational context 
or study subjects’ perceptions of organizational context. Often specific frameworks do 
not specify whether the organizational context should be assessed objectively or from a 
subject’s point of view, rather the researcher decides in operationalizing the model and 
collecting the data.  For example, in Choi’s work on innovation-use behavior, the model 
includes both individual characteristics and organizational context (2004).  
 An innovation is defined as an idea, practice, or object that is perceived as new 
by an individual or organization (Rogers, 1983). The decision to adopt an innovation 
often may occur at the organizational level, but individuals within the organization also 
have to decide whether they are going to use (i.e., accept) the innovation. Therefore, 
innovation-use behavior is often defined as either the intended or continued use of an 
innovation by an individual. It can be measured as frequency and/or intensity of 
innovation use (Frambach & Schilewaert, 2002). Choi’s innovation-use model suggests 
that personal characteristics such as personal values, attitudes and abilities mediate 
and/or moderate the relationship between organizational culture, norms, support and 
the outcome, innovation-use behavior (2004). The framework does not specifically 
include any perceptions of context. In operationalizing the model, however, Choi elected 
to use employee’s perceptions of organizational climate, norms, and support instead of 
collecting objective measures of context. For example, instead of assessing the number 
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of trainings provided, he asked employees if they felt that had received enough training.  
 In the second approach, researchers incorporate context through a model of 
climate, where individual perceptions mediate the relationship between objective 
measures of context and personal characteristics in predicting an outcome. James and 
Jones suggest that objective characteristics of the organizational context are 
antecedents of climate, while individuals’ interpretive perceptions provide meaning to 
the context (1974). This view proposes that individual climate perceptions are a result of 
both organizational objective contextual factors and personal characteristics (Kozlowski 
& Klein, 2000).  For example, the integrative model for continually “updating” an 
individual’s knowledge and skills as to stay current with the latest innovations (i.e., an 
individual-level behavior) includes both personal characteristics and contextual factors 
(Kozlowski & Farr, 1988).  The framework suggests that individual perceptions of the 
climate mediate the relationship between personal characteristics (e.g., age, 
experience, tenure), organizational context (e.g., technology use, structure) and 
individual performance, including the ability to “update.”  
 In this research, we have the unique ability to be able to test all of these 
approaches of incorporating context, as the data were collected from CCOP 
administrators and CCOP physicians and includes both types of measures of context. 
Specifically, Aim 1 examined the objective measures of organizational context. Aim 2 
utilized the perceptions of organizational context, while Aim 3 included both objective 
measures of context and perceptions of context. Therefore this research is significant as 
we were able to comprehensively examine the impact of organizational context and 
personal characteristics on physician enrollment. 
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Innovation Implementation Frameworks  
 Given the objective to include organizational context in multiple ways, we 
required three separate conceptual frameworks to guide the research, one for each aim. 
Interestingly, although there are a number of models for innovation implementation or 
implementation effectiveness at the organizational level, overall there are very few 
models that examine implementation at the individual level. The majority of past 
research has either focused on the individual acceptance of technologies, such as the 
Technology Acceptance Model and the Unified Theory of Acceptance and Use of 
Technology, or has examined individual-level behavior without incorporating 
organizational context within the model, such as the Theory of Planned Behavior (Davis, 
1989) (Venkatesh et al., 2003) (Ajzen, 1991). 
 One model that considers both individual- and organizational-level factors in 
predicting individual innovation acceptance is the Multilevel Framework of 
Organizational and Individual Innovation Adoption (Frambach & Schilewaert, 2002). The 
Multilevel Framework of Organizational and Individual Innovation Adoption suggests 
that individual innovation acceptance is based on objective organizational contextual 
factors such as trainings offered, incentives rewarded, support provided, peer usage of 
the innovation, and expectations as well as personal characteristics such as attitudes, 
values, and demographics (Frambach & Schilewaert, 2002). We used this model to 
guide our analysis in Aim 1. The model is based only on objective assessments of 
organizational context, however, and thus is not relevant for the other two aims.  
 There are no current models that incorporate perceptions of organizational 
context with individual-level determinants such as values, demographics, and 
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experience. Therefore in Aims 2 and 3, we adapted the theory of innovation 
implementation (Klein & Sorra, 1996) to explain individual level implementation 
effectiveness. Specifically in Aim 2, we tested whether innovation-values fit moderates 
the effect of perceptions of implementation climate on enrollment (i.e., implementation 
effectiveness). In Aim 3, we incorporated objective assessments of context and tested 
whether perceptions of implementation climate mediates the relationship between 
objective assessments of organizational policies and practices that encourage 
implementation and enrollment. These models are discussed in detail in Chapters 5 and 
6 respectively.  
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CHAPTER 3: STUDY DESIGN AND METHODS  
 
Overview and Rationale  
 
This dissertation was a secondary analysis of data collected directly from CCOP 
physicians and administrators, annual CCOP Progress reports, and the AMA Physician 
Masterfile. The aims utilized a concurrent cross-sectional design to examine both the 
physician characteristics and organizational contextual factors associated with patient 
enrollment in NCI-sponsored cancer clinical trials. Each aim employed a separate 
conceptual framework. More detailed descriptions of the conceptual models are 
provided in Chapters 4-6 respectively. The dependent variable for all three aims is the 
number of patients physicians enroll in NCI-sponsored cancer clinical trials in 2011. Key 
physician variables included physicians’ attitudes and values (Aims 1 and 2), as well as 
characteristics such as experience, medical specialty, and training (All three aims). Key 
organizational-level variables include organizational contextual factors, such as policies 
and practices to support implementation (e.g., trainings offered, support provided, 
expectations instituted) (Aims 1 and 3). In the first aim, contextual factors were 
incorporated by including objective measures of organizational context gathered as part 
of the CCOP Administrator Survey. In the second aim, organizational context was 
included as perceptions of organizational context as assessed by CCOP-affiliated 
physicians as part of the CCOP Physician Survey. Lastly, in the third aim organizational 
context included both objective measures and perceptions of organizational context.   
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Research Questions and Hypotheses 
 
Aim 1 Research Question: What are the physician characteristics and objective 
assessments of organizational context associated with higher enrollment of patients in 
NCI-sponsored cancer clinical trials? 
Aim 1 Main Hypothesis: Personal characteristics (e.g., specialty, experience), 
attitudes towards the CCOP program, and organizational context (e.g., training, 
support, expectations) will directly influence physician enrollment of patients in 
clinical trials. In addition, personal characteristics and organizational context will 
have indirect effects on enrollment operating through attitudes.  
 
Aim 2 Research Question: What are the physician characteristics and physicians’ 
perceptions of organizational context associated with higher enrollment of patients in 
NCI-sponsored cancer clinical trials?  
Aim 2 Main Hypothesis: Physicians’ perceptions of how the innovation fits with 
their values will moderate the role between their perceptions of innovation 
climate (i.e., a climate that supports, rewards, provides expectations regarding 
participating in CCOP) and physician enrollment of patients in clinical trials.  
 
Aim 3 Research Question: Are objective assessments of organizational context and 
physicians’ perceptions of organizational context associated with higher enrollment of 
patients in NCI-sponsored cancer clinical trials?  
Aim 3 Main Hypothesis: Physician perceptions of implementation climate will 
mediate the effect of objective assessments of organizational implementation 
policies and practices on physician enrollment of patients in trials.  
 
Data  
Data for this dissertation came from four sources: 1) 2011 Annual CCOP 
Progress Reports; 2) 2011 CCOP Administrator Survey; 3) 2011 CCOP-Affiliated 
Physician Survey; and 4) 2012 AMA Physician Masterfile. Data from all four sources 
were linked and de-identified for each respective analysis (Table 1).  
2011 Annual CCOP Progress Reports. Each March, every CCOP (n=47) submits 
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a progress report to NCI detailing the previous nine-month’s research and enrollment 
activities. The report includes standardized questions regarding the allocation of CCOP 
resources, staffing assignments, total cancer patient volume, the number of open 
cancer clinical trials, the total number of patients each CCOP enrolls, as well as the total 
number of patients each individual CCOP-affiliated physician enrolls. This study utilized 
the 2011 Progress Reports submitted in March 2012, which cover the period from June 
2011 to February 2012. The 2011 Progress Reports overlap in timing with the 2011 
CCOP Administrator and CCOP-Affiliated Physician Surveys. Specifically, the progress 
reports were used in all three aims to determine the dependent variable as well as to 
determine if a physician was the CCOP Principal Investigator (PI). Average physician 
enrollment by CCOP was also used in Aim 1.  
2011 CCOP Administrator Survey. As part of the Implementing System 
Intervention to Close the Discovery-Delivery Gap Grant (5R01CA124402), we 
conducted a survey of CCOP administrators in Fall 2011. The goal was to learn more 
about how the CCOPs are organized and how they operate. All CCOP administrators 
participated (n=47) in the survey. The survey asked specific questions regarding the 
CCOP organizational structure, sponsored educational trainings, physician resources 
and support for screening, consenting, and enrolling patients, as well as CCOP staffing 
procedures. Specifically, Administrator Survey was used to assess the objective 
organizational context factors in Aims 1 and 3.  
2011 CCOP-Affiliated Physician Survey. Also as part of the Implementing 
System Intervention to Close the Discovery-Delivery Gap Grant, we also conducted a 
survey of CCOP- physicians in Fall 2011. The goal of this survey was to learn more 
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about physician participation in the CCOP program. The survey did not include 
physicians who practice at one of the 15 MB-CCOP. The physician survey asked 
specific questions regarding physicians’ perceptions regarding expectations for 
enrollment, research support provided by the CCOP, ability to provide input, how well 
they are kept informed of CCOP activities, recognition received from the CCOP, as well 
as personal beliefs, attitudes, and values regarding the importance of cancer clinical 
trials. Specifically, the physician survey was used to assess personal characteristics 
and attitudes in Aim 1. It was also used to determine innovation-values fit in Aim 2. In 
addition, it was used to for the physicians’ perceptions of climate in Aims 2 and 3.  
2012 AMA Physician Masterfile. Established by the AMA in 1906, the Physician 
Masterfile includes current and historical data for more than 1.4 million physicians, 
residents, and medical students in the U.S. This includes approximately 400,000 foreign 
medical graduates practicing in the U.S. A record is established when individuals enter 
medical school, or in the case of international medical graduates, upon entry into a post-
graduate residency or when they obtain a U.S medical license. The AMA Masterfile 
contains demographic information, such as age and gender, as well as specialty, 
experience, and medical school training and residency. The Masterfile also contains 
information on practice location, type, and size. Specifically, the Masterfile was used to 
characterize the physicians in the sample. Demographics, expertise, and experience 
were included in the model for all three aims.  
Study Sample   
The sample for all three aims was comprised of physicians who responded to the 
2011 CCOP-Affiliated Physician Survey. Responses were collected between October 
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2011 and January 2012.  We surveyed a total of 817 physicians across all 47 CCOPs. 
We achieved a response rate of 59%, which was in the range of rates previously 
reported (45% to 79%) (Kellerman & Herold, 2001). Therefore, the final sample includes 
485 physicians of whom, 74% were male and 26% were female (Table 2). In addition, 
approximately 75% were White non-Hispanic, 15% were Asian, and the remaining 10% 
were either African-American, Native Hawaiian/Pacific Islander, or reported multiple 
races. The average age was 53 years old (range 34 to 82) with an average of 26 years 
experience (range 8 to 57). Physicians on average enrolled approximately 5 patients a 
year in 2011 (range 0 to 62) with a standard deviation of 8 patients. The vast majority 
practiced in a group practice (78%) and trained in the U.S (80%). In addition, 40% 
reported hematology oncology as their primary specialty, 21% reported radiation 
oncology, 11% reported general non-specialized oncology, 10% reported some type of 
surgery, and the remaining 18% reported either general practice, gynecology oncology, 
pediatric oncology, or other type of specialist as their medical specialty.  
In addition to generating the descriptive statistics for actual survey respondents, 
we also examined the descriptive statistics among non-survey respondents, the entire 
sample of surveyed CCOP physicians, and the population of all CCOP physicians to 
ensure the sample was not subject to any biases. There were two significant differences 
between survey respondents and non-respondents.  First, in terms of specialty, 
respondents were less likely to be medical oncologists (11% vs. 24%) and more likely to 
be surgeons (10% vs. 5%).   Second, responders were more likely to enroll patients in 
cancer trials: an average 5 patients per year (range 0 to 62; standard deviation of 8) 
compared to only 3 patients per year among the non-respondents (range 0 to 88; 
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standard deviation of 7.5).  
We also tested to see if there were any significant differences between those that 
were sampled compared to the CCOP physician population. Our sample was slightly 
over representative of physicians practicing in group practices (79% v. 72%) and 
hospitals (12% v. 11%), and slightly under representative of physicians in solo practices 
(2% v. 5%) and surgeons (8% v. 10%). In addition, those that were sampled enrolled on 
average 4 patients per year in 2011 (range 0 to 88; standard deviation 8) compared to 
those that were not sampled, which only enrolled on average 2 patients per year (range 
0 to 44; standard deviation 4).  Although these differences were statistically significant, 
overall they are not likely to significantly influence the generalizability of study findings.  
Overview of Statistical Analyses  
Intraclass Correlations and Interrater Agreement  
 
For each physician survey question, we tested the consistency in responses of 
members of the same CCOP compared to members in different CCOPs by calculating 
intraclass correlation coefficients, ICC(1) and ICC(2).  This provided a sense of the 
proportion of group-level variance accounted for by group membership. In addition, we 
also tested the within-group interrater agreement by calculating r*WG(J) indices. Overall 
the results indicate that there was substantial variation in responses (Table 3). The 
ICC(1) values were low, and the ICC(2) values which vary as a function of the ICC(1) 
values and the sample size, were also modest.  
The interrater agreement statistics demonstrated that for some measures, such 
as affect (r*WG(J) =0.77) and values (r*WG(J) =0.82), there was strong agreement among 
physicians within a CCOP. There was also strong agreement for the measures that 
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composed the innovation-values fit construct (Want offer trials r*WG(J) =0.88; 
Participating important r*WG(J) =0.79; Value participating r*WG(J) =0.82; Explore important 
issues r*WG(J) =0.77). For other measures, however, such as beliefs regarding the 
complexity (r*WG(J) =0.32) and exclusively (r*WG(J) =0.41) of the trials there was only 
modest agreement. The inter-rater agreement statistics were also modest for perceived 
expectations for the number of patients physicians are expected to enroll (r*WG(J) =0.01) 
and for the support needed to identify (r*WG(J) =0.27) and enroll patients (r*WG(J) =0.37). 
Physicians also disagreed as to whether they were recognized (r*WG(J) =0.23) and 
appreciated (r*WG(J) =0.21) for enrolling patients. Although many of these results indicate 
that several of the constructs could be assessed at the group level (i.e., innovations-
value fit), we were most interested in examining enrollment at the individual physician 
level.  
Structural Equation Modeling  
For each aim, we utilized SEM to analyze the results. There are many 
advantages of using SEM. For example, SEM allows researchers to test latent 
constructs that are not directly assessed, but rather are composed of observed data 
(e.g., attitudes, innovation-values fit, perceptions of implementation climate, 
organizational context). SEM also takes into account measurement error by including 
error variables in the error portions of the observed variables; therefore conclusions 
about relationships are not biased by any measurement error. SEM is also 
advantageous as researchers are able to test complex frameworks that include 
mediation and moderation in a single model (as compared to regression that may 
require multiple analyses). Therefore, SEM allows researchers to easily examine 
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indirect and direct effects of variables on the outcome (Werner & Schermelleh-Engel, 
2009).  
There are five main steps involved in SEM. First, we specified each model. 
Second, we checked to ensure the model was identified, which means the number of 
parameters must be less than or equal to the number of observations (Norman & 
Streiner (eds), 2003). Third, we worked to fit and evaluate the model. We used 
maximum likelihood estimation techniques, given we had very little data missing. We 
also used clustered-robust standard errors as errors were likely correlated and we 
wanted to adjust for the 47 CCOPs. We then tested the fit of the model using the typical 
goodness-of-fit statistics. We examined the root mean square error of approximation 
(RMSEA), and the associated confidence interval and p-value. RMSEA values below 
0.06 are considered acceptable with an upper bound of the confidence interval lower 
than 0.1. We also examined the Comparative Fit Index (CFI) and the Tucker-Lewis 
Index (TLI), and the standardized root mean squared residuals (SRMR).  The CFI and 
TLI ideally should be above 0.90, and an ideal SRMR should be close to zero (lower 
than 0.08 is considered acceptable) (Norman & Streiner (eds), 2003) (Schreiber et al., 
2006). Fourth, we modified the original models and made any necessary changes to 
improve fit (e.g., add covariances). Lastly, after we achieved the best fitting model, we 
interpreted the model and examined estimated standardized path coefficients and 
corresponding standard errors. The general mathematical formula for SEM is as follows:  
Equation 1:  Υ = ΒΥ + ΓΧ + α + ζ 
Where Υ on the left hand side is the endogenous outcome variable, individual physician 
enrollment of patients in NCI-sponsored cancer clinical trials, and Υ on the right hand 
26 
 
side is composed of the observed endogenous measures (γ) and latent endogenous 
constructs (η). Χ represents both the observed exogenous measures (x) and the latent 
exogenous constructs (ξ). Β and Γ are the coefficient estimates for the endogenous and 
exogenous variables, α are the intercepts, and ζ represents the error (e.η e.γ) 
associated with the model. I can also estimate κ, the means of the exogenous variables, 
Φ, the variances and covariances of the exogenous variables, and Ψ, the variances and 
covariances of the error terms.  
Study Size and Power  
 
The general rule regarding sample size for SEM is that 5 to 10 subjects per 
parameter included in the model are needed. In SEM, the number of parameters is 
based on: 1) the number of pathways in the model; 2) the number of variances for the 
exogenous variables; 3) the number of covariances in the model; and 4) the number of 
disturbance terms for the endogenous variables. For Aim 1, we had 64 parameters (44 
pathways, 10 variances for exogenous variables, 8 covariances, and 2 disturbance 
terms). For Aim 2, we had 47 parameters (33 pathways, 10 variances, 3 covariances, 
and 1 disturbance term). Lastly for Aim 3, we had 73 parameters (52 pathways, 12 
variances, 7 covariances, and 2 disturbance terms). Thus we needed a minimum of 365 
to 730 physicians in the sample. Although we only had 485 physicians in the sample, 
we did not encounter any problems using SEM given all three models were identified.  
Model identification is critical in analyzing SEM.  Identification requires that the 
number of observations is greater than the number of parameters. The number of 
observations is equal to (K*(K+1))/2, where k= number of variables. Thus, our number 
of observations are: 231 for Aim 1 (21 variables), 210 for Aim 2 (20 variables), and 392 
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for Aim 3 (27 variables). Thus the models were identified for all three aims.  
• Aim 1: 231 observations > 64 parameters  
• Aim 2: 210 observations > 47 parameters  
• Aim 3: 392 observations > 77 parameters  
Power is often assessed after a model is specified and can be based of certain fit 
indices, such as the RMSEA. According to the method developed by MacCallum, 
Browne, and Sugawara (1996) to calculate the power of a structural equation model, 
you need five factors: the degrees of freedom, significance level (α), sample size, a null 
value of RMSEA, and the alternative value of RMSEA. The null RMSEA value used 
tends to be 0.00, indicating a perfect fit. For Aim 1 the degrees of freedom was 165, for 
Aim 2 it was 139, and for Aim 3 it was 202. Using an α=0.05, a null RMSEA value of 
0.00 and alternative RMSEA value of 0.05 (common values used for testing exact fit), 
and a sample size of at least 400, the models for all three aims were 100% powered 
(MacCallum et al., 1996).  
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Table 1: Variables, Measures, and Data Sources for All Aims 
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CCOP$Survey$
Respondents$n=485
CCOP$Survey$Non7
Respondents$n=332
CCOP$Entire$Sample$
n=817
All$CCOP$Physicians$
n=2725
Mean%or%Proportion%of%
Sample%
Mean%or%Proportion%of%
Sample%
Mean%or%Proportion%of%
Sample%
Mean%or%Proportion%of%
Sample%
2011%Patient%%Enrollment%
4.7*%
(8.1)
Range:%0,%62
3.4
(7.5)
Range:%0,%88
4.2**
(7.9)
Range:%0,%88
2.7%
(5.9)
Range:%0,%88
Age 52.6
(9.8)
Range:%34,82
52.8
(9.6)
Range:%34,%76
52.7
(9.7)
Range:%34,%82
52.5%
(9.8)
Range:%32,%90
Practice$Type
!!!Group!Practice 78% 81% 79%** 72%
%%%Hospital 12% 12% 12%** 11%
!!!Solo!Practice 4% 5% 2%** 5%
!!Other/None!Listed 6% 2% 7% 12%
Training$Location$
!!!U.S!Trained 80% 76% 78% 79%
!!!Non!U.S!Trained 20% 24% 22% 21%
Experience$ 25.7
(10.1)
Range:%8,%57
26.0
(10.0)
Range:%9,51
28.5
(10.1)
Range,%8,57
25.7
(10.2)
Range:%2,58
Medical$Specialty$
!!!General!Practice 5% 5% 5% 5%
!!!Gynecological!Oncology 4% 3% 4% 3%
!!!Hematology!Oncology 40% 39% 40% 31%
!!!Medical!Oncology 11%* 24% 16% 22%
!!!Other!Specialist! 4% 4% 4% 5%
!!!Pediatric!Oncology 5% 3% 5% 4%
!!!Radiation!Oncology 21% 16% 19% 19%
!!!Surgery! 10%* 5% 8%** 10%
Gender
!!!Male 74% 71% 72.5% 74.6%
!!!Female! 26% 29% 27.5% 25.4%
Descriptive*Variables
Outcome*
Table$2:$Descriptive$Statistics$All$Three$Aims$
Pediatric!Oncology%includes%child%neurology,%emergency%medicine%J%pediatrics,%pediatric%hematology%oncology,%pediatrics,%pediatric%surgery%
Other!specialist%includes%anatomic%pathology,%anesthesiology,%cardiovascular%disease%,%dermatology,%endocrinology,%
gastroenterology,%neurology,%otolaryngology,%pain%medicine,%psychiatry,%pulmonary%disease,%rheumatology,%urology
Standard%deviations%in%parentheses%
*%Indicates%significant%difference%between%survey%respondents%and%nonJrespondents%at%.05%significance%
**Indicates%significant%difference%between%sample%and%population%at%.05%significance%
Surgery%includes%abdominal%surgery,%colon%and%rectal%surgery,%critical%care%sugary,%dermatologic%surgery,%general%surgery,%
neurological%surgery,%orthopedic%surgery,%plastic%surgery,%surgical%oncology,%spinal%cord%injury,%thoracic%surgery,%urological%
General!practice%includes%addiction%medicine%emergency%medicine,%family%practice/medicine,%geriatric%medicine,%hospice%and%palliative%medicine,%general%practice,%preventative%medicine,%internal%medicine
Gynecological!oncology!includes%gynecological%oncology,%general%gynecology,%gynecological%surgery%
Hematology!oncology%includes%blood%banking,%hematology%oncology,%hematology
Oncology%includes%medical%oncology,%oncology
Radiation!Oncology%includes%diagnostic%radiology,%nuclear%medicine,%radiation%oncology,%radiology,%vascular%and%interventional%radiology
Table 2: Descriptive Statistics, All Three Aims 
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Table 3: Intraclass Correlations and Interrater Agreement Statistics for Physician Survey 
Questions 
Construct) Measure) Aim(s) ICC(1) ICC(2)
Average)
R*WG(J)
%)Significant
)R*WG(J)
Attitudes:)Affect NCI/sponsored)trials)explore)clinical)issues)that)
are)important)in)my)practice)
1 0.00)
(0.02)
/0.04 0.77 89%
Attitudes:)Beliefs) NCI/sponsored)trials)exclude)too)many)patients) 1 0.07*
()0.03)
0.44 0.41 40%
Attitudes:)Beliefs) NCI/sponsored)trials)are)too)complex)to)do)in)my)
practice)
1 0.08*
()0.03)
0.46 0.32 36%
Attitudes:)Values) I)value)participating)in)NCI/sponsored)clinical)
trials
1 0.01
()0.02)
0.09 0.82 94%
1
0.06*
(0.03) 0.38 0.96 100%
Innovation/Values)Fit I)want)to)offer)NCI/sponsored)clinical)trials)to)my)
patients)
2 0.00)
(0.02)
0.00 0.88 98%
Innovation/Values)Fit Participating)in)NCI/sponsored)clinical)trials)is)
important)to)me)
2 0.02
(0.02)
0.18 0.79 91%
Innovation/Values)Fit I)value)participating)in)NCI/sponsored)clinical)
trials
2 0.01
()0.02)
0.09 0.82 94%
Innovation/Values)Fit NCI/sponsored)trials)explore)clinical)issues)that)
are)important)in)my)practice)
2 0.00)
(0.02)
/0.04 0.77 89%
2 0.01
()0.02)
0.10 0.92 100%
Perceptions)of)Implementation)
Climate:))Rewards
I)receive)appreciation)when)I)enroll)patients)in)
NCI/sponsored)clinical)trials
2)&)3 0.05*
(0.03)
0.36 0.21 15%
Perceptions)of)Implementation)
Climate:))Rewards
I)receive)recognition)when)I)enroll)patients)in)
NCI/sponsored)clinical)trials
2)&)3 0.07*
(0.03)
0.45 0.23 21%
Perceptions)of)Implementation)
Climate:))Expectations
I)am)expected)to)help)the)CCOP)meet)its)patient)
enrollment)goals)in)NCI/sponsored)clinical)trials)
2)&)3 0.03
(0.02)
0.22 0.41 47%
Perceptions)of)Implementation)
Climate:))Expectations
I)am)expected)to)enroll)a)certain)number)of)
patients)in)NCI/sponsored)clinical)trials
2)&)3 0.14*
(0.04)
0.63 0.01 11%
Perceptions)of)Implementation)
Climate:))Support
I)get)the)research)support)that)I)need)to)identify)
potentially)eligible)patients)for)NCI/sponsored)
clinical)trials
2)&)3
0.07*
)(0.03) 0.44 0.27 26%
Perceptions)of)Implementation)
Climate:))Support
I)get)the)research)support)that)I)need)to)enroll))
patients)in)NCI/sponsored)clinical)trials)(e.g.,)
consenting)patients)
2)&)3
0.08*
()0.03) 0.48 0.37 38%
2)&)3 0.08*
()0.03)
0.47 0.88 100%
Standard'Errors'in'Parenthesis'
*'Statistically'Significant'
Table)3:)Intraclass)Correlations)and)Interrater)Agreement)Statistics)for)Physician)Survey)Questions
Latent)Construct:)Attitudes)
Latent)Construct:)Innovation/Values)Fit)
Latent)Construct:)Implementation)Climate
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CHAPTER 4: ORGANIZATIONAL AND PHYSICIAN FACTORS ASSOCIATED WITH 
PATIENT ENROLLMENT IN CANCER CLINICAL TRIALS 
 
Overview  
Our purpose was to identify physicians’ individual characteristics, attitudes, and 
organizational contextual factors associated with higher enrollment of patients in cancer 
clinical trials among physician participants in the National Cancer Institute (NCI)’s 
Community Clinical Oncology Program (CCOP). We hypothesized that physicians’ 
individual characteristics, such as age, medical specialty, tenure, CCOP organizational 
factors (i.e., policies and procedures to encourage enrollment), and attitudes towards 
participating in CCOP would directly determine enrollment. We also hypothesized that 
physicians’ characteristics and CCOP organizational factors would influence physicians’ 
attitudes towards participating in CCOP, which in turn would predict enrollment. We 
evaluated enrollment in NCI-sponsored cancer clinical trials in 2011 among 481 
physician participants using structural equation modeling. The data sources include 
CCOP Annual Progress Reports, two surveys of CCOP administrators and physician 
participants, and the American Medical Association Masterfile.  
Physicians with more positive attitudes towards participating in CCOP enrolled 
more patients than physicians with less positive attitudes. In addition, physicians who 
practiced in CCOPs that had more supportive policies and practices in place to 
encourage enrollment (i.e., offered trainings, provided support to screen and enroll 
patients, gave incentives to enroll patients, instituted minimum accrual expectations)
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also significantly enrolled more patients. Physician status as CCOP Principal 
Investigator (PI) had a positive direct effect on enrollment, while physician age and non-
oncology medical specialty had negative direct effects on enrollment. Neither 
physicians’ characteristics nor CCOP organizational factors indirectly influenced 
enrollment through an effect on physician attitudes.  
We examined whether individual physicians’ characteristics and attitudes, as well 
as CCOP organizational factors, influenced patient enrollment in cancer clinical trials 
among CCOP physicians.  Physician attitudes and CCOP organizational factors had 
positive direct effects, but not indirect effects, on physician enrollment of patients. Our 
results could be used to develop physician-directed strategies aimed at increasing 
involvement in clinical research. For example, administrators may want to ensure 
physicians have access to support staff to help screen and enroll patients or institute 
minimum accrual expectations. Our results also highlight the importance of recruiting 
physicians for volunteer clinical research programs whose attitudes and values align 
with programmatic goals. Given that physician involvement is a key determinant of 
patient enrollment in clinical trials, these interventions could expand the overall number 
of patients involved in cancer research. These strategies will be increasingly important 
as the CCOP network continues to evolve.  
Background  
Cancer clinical trials are instrumental for developing innovative cancer treatments 
and expanding current diagnostic, control, and prevention techniques (Sorbye et al., 
2009) (Grunfeld et al., 2002). Despite the potential for positive health outcomes, only 3-
5% of U.S adults with cancer participate in cancer clinical trials (NCI Cancer Bulletin, 
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2010). To increase patient participation in trials, the CCOP, a cancer focused provider-
based research network administered by the NCI, engages community physicians in 
clinical research to enhance the translation of research results into practice (NCI, 2010). 
Since its inception in 1983, the CCOP network overall has generated over 50% of the 
enrollment in NCI-sponsored cancer prevention and control trials and 30% of the 
enrollment in NCI-sponsored cancer treatment trials (Minasian et al., 2010)   
Although the CCOP network has successfully increased cancer clinical trial 
enrollment, individual physicians vary in their enrollment of patients in clinical trials. 
Many participating physicians enroll no patients in a given year, while others enroll 
dozens. In 2011, approximately 40% of CCOP physicians enrolled no patients (mean: 3; 
range: 0-88). Variation in physician enrollment has occurred since the program’s 
inception, yet the reasons have not been systematically investigated. Research to date 
has focused on identifying the organizational and environmental contextual factors that 
drive clinical trial enrollment at the CCOP, rather than the individual, level (Kaluzny et 
al., 1995) (Carpenter et al., 2012) (Weiner et al., 2012) (Jacobs et al., 2013). No 
research has examined physician and organizational contextual factors associated with 
physicians’ success in enrolling patients. These findings are critical to determine the 
context within which we can increase enrollment of cancer patients in NCI-sponsored 
cancer clinical trials and, in turn, the pace at which we identify and disseminate 
innovative therapies. Understanding factors that drive physician accrual will be critical in 
the organizational design of the new NCI Community Oncology Research Program 
(NCORP), for example, by setting minimum expectations for enrollment, recognizing 
high enrolling physicians, or providing physicians with support (NCI, 2013). Findings can 
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also inform physician recruitment efforts for NCORP.   
This study seeks to identify the specific CCOP-affiliated physicians’ 
characteristics and organizational contextual factors associated with higher enrollment 
of patients in NCI-sponsored cancer clinical trials. The hypothesis is that organizational 
contextual factors, such as trainings, support to enroll patients, expectations for 
enrollment, physicians’ attitudes towards participating in clinical trials, and individual 
characteristics, such as age, tenure, medical specialty will directly and indirectly affect 
their enrollment of patients in trials. 
Methods  
Theoretical Framework  
The conceptual model is adapted from the Multilevel Framework of 
Organizational and Individual Innovation Adoption (Frambach & Schilewaert, 2002). 
Although this framework was developed in the marketing and management literature, it 
has become a common approach to address innovation implementation in health and 
human services research as well.  For example, the framework has been integrated as 
part of the Consolidated Framework for Implementation Research, which seeks to 
advance the implementation of health services research findings into practice [12]. An 
attractive feature of this framework is that it includes factors at both the organizational 
and individual levels to predict innovation adoption (Damschroder et al., 2009). In this 
study we focused on adoption among individual physicians.  
The original model as developed by Frambach and applied to this setting is 
presented in Figure 1. The model postulates that social usage of the innovation, such as 
social norms, expectations, peer usage, and personal disposition towards 
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innovativeness (i.e., tendency to accept an innovation regardless of others) directly 
determines individual innovation acceptance. Innovation acceptance in this study is 
participation in clinical trials, defined as the number of patients CCOP physicians 
enrolled in NCI-sponsored cancer clinical trials in 2011. The model also suggests that 
social usage and personal disposition towards innovativeness determines individuals’ 
attitudes towards using the innovation, which in turn determines innovation acceptance. 
Also included in the model are organizational facilitators (e.g., training, support, 
incentives) and individual characteristics (e.g., demographics, experience) that may also 
indirectly influence innovation acceptance through individuals’ attitudes and personal 
disposition towards innovativeness respectively.  
The model we tested adheres to the basic structure of the framework proposed 
by Frambach (2002); however, based on data availability, theory, and knowledge of 
CCOP network operation, we made three changes to the original model before 
analyzing any data. The tested model is presented in Figure 2. First, we combined 
social usage and organizational facilitators into one construct, organizational context. 
We did this for two reasons: (1) it makes theoretical sense as all the data used for this 
construct is at the CCOP level and (2) we only had two observed variables, peer 
enrollment and expectations, to construct social usage, but the statistical modeling 
approach required we use at least three observed variables (O’Brien, 1994).   The 
second change is that we did not include personal disposition towards innovativeness in 
our model because we lacked data on this construct. Lastly, we included individual 
values as a component of attitudes rather than an individual characteristic. We decided 
to do this because our survey instrument included values, along with general affect, 
 36 
 
beliefs towards the ease of participation, and complexity of clinical trials as components 
of attitudes towards innovation adoption. Therefore it made theoretical sense to include 
values as a component of attitudes versus an individual characteristic.  
Study Setting and Sample  
The CCOP network is a joint venture between the NCI Division of Cancer 
Prevention, which provides overall direction and funding for community hospitals and 
physicians to participate in clinical trials, clinical cooperative groups, and community-
based physicians and hospitals (Kaluzny et al., 1994). The CCOP research bases 
design and conduct clinical trials, and individual community-based physicians and 
hospitals assist with patient enrollment, data collection, and dissemination of study 
findings (Minasian et al., 2010) (Kaluzny et al., 1994) When the data were collected in 
2011, 47 CCOPs operated in 28 states with approximately 3,000 participating 
community physicians.  
The sample is comprised of physicians who responded to the 2011 CCOP 
Physician Survey. We used a stratified (by CCOP) random sample of 817 physicians 
across all 47 CCOPs. The final sample included 485 physicians (59.4% of the total 
physicians surveyed). The only significant (p<0.05) differences between survey 
responders and non-responders were that responders enrolled more patients per year 
(4.7 versus 3.4), were more likely to be a surgeon (10% versus 5%), and were less 
likely to be a non-specialized general oncologist (11% versus 24%).   There were no 
significant differences between respondents and non-respondents regarding gender, 
race, age, practice type, training location, and tenure. This study was determined to be 
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at Chapel Hill.  
Study Design and Data Sources  
The data for this cross-sectional study were obtained from four sources. The 
2011 CCOP Progress Reports provided data on physicians’ enrollment activity from 
June 1, 2011 to February 29, 2012. The 2011 CCOP Administrator Survey and the 2011 
CCOP Physician Survey were both administered as part of a larger NCI-funded-study 
(5R01CA124402). The Physician Survey supplied data on CCOP physicians’ attitudes 
towards participation in clinical trials. Responses were collected between October 2011 
and January 2012.  The Administrator Survey provided information on the CCOP 
organizational contextual factors. The majority of responses were collected at the 
annual CCOP meeting in September 2011. Any remaining surveys were completed in 
October 2011. We achieved a 100% response rate from CCOP Administrators. Lastly, 
the 2012 American Medical Association Physician Masterfile provided data on CCOP 
physicians’ individual characteristics.  
Measures  
Table 4 provides details on our measures. The outcome was the number of 
patients CCOP-affiliated physicians enrolled in NCI-sponsored cancer clinical trials in 
2011. Physician attitudes, a predictor construct, was composed of questions assessing 
beliefs related to the complexity of trials, whether trials excluded too many patients, 
affect towards whether trials explored important issues, and physicians’ values related 
to participating in clinical trials. Organizational contextual factors, also a predictor 
construct, included educational trainings offered, support provided by the CCOP to 
physicians to help screen and enroll patients, incentives provided to physicians, peer 
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usage (i.e., the average number of patients enrolled in NCI-sponsored clinical trials for 
physicians within a specific CCOP), and CCOP expectations for enrollment.  Physicians’ 
individual characteristics included age, practice type, tenure, physician training location, 
medical specialty, and whether or not the physician is the CCOP Principal Investigator 
(PI).  
Statistical Analysis  
SEM with maximum likelihood estimation was used to simultaneously test the 
effects of the latent constructs in our conceptual model (i.e., organizational contextual 
factors, physician attitudes) on enrollment. SEM is composed of multivariate regression 
models and can be used to estimate proposed causal relationships (Norman & Streiner 
(eds), 2003) (Schreiber et al., 2006).  We used confirmatory SEM to test the 
hypothesized pathways among factors represented in Figure 2 by comparing how well 
this proposed structure fits the observed data. We elected to use SEM because it 
allowed us to test for constructs that are not directly assessed, but are instead 
composed of observed indicators representing the constructs of interest (e.g., CCOP 
organizational contextual factors, physician attitudes). We elected to use clustered 
robust standard errors to account for clustering of physicians within 47 CCOPs. We 
evaluated model fit using the Comparative Fit Index (CFI) and the Tucker-Lewis Index 
(TLI). CFI and TLI values range from 0 to 1, with values ≥ 0.90 representing adequate fit 
(Norman & Streiner (eds), 2003) (Schreiber et al., 2006). We also examined the root 
mean square error of approximation (RMSEA), and the associated confidence interval 
and p-value. RMSEA values < 0.05 and an upper bound of the confidence interval < 0.1 
are considered acceptable (Norman & Streiner (eds), 2003) (Schreiber et al., 2006). 
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Next, we examined the standardized root mean squared residuals (SRMR), with values 
< 0.08 considered acceptable fit (Norman & Streiner (eds), 2003) (Schreiber et al., 
2006). We also evaluated our model by testing the significance of all standardized 
estimates, including the direct and indirect effects of variables on the outcome.  
Based on these fit statistics for the original model in Figure 2, we elected to re-
specify the model to improve its fit. SEM is an iterative process in which model fit is 
improved by using theory and modifications indices either to add additional pathways 
between variables or to allow items to co-vary (Norman & Streiner (eds), 2003) 
(Schreiber et al., 2006). Modification indices are the minimum that the chi-square 
statistic is expected to decrease if the corresponding parameter is no longer assumed to 
be fixed at zero (Norman & Streiner (eds), 2003) (Schreiber et al., 2006).  When 
revising the model, we tested whether model fit improved by comparing the baseline 
model with the new model using the Lagrange multiplier test and fit statistics. 
Once we achieved a well-fitting model, we tested the significance of all 
standardized estimates, including direct and indirect effects. Standardized parameter 
estimates are transformations of unstandardized estimates that remove scaling and can 
be used for informal comparisons of parameters throughout the model (Schreiber et al., 
2006). Direct effects are equal to the regression coefficients (i.e., β) while indirect 
effects are the product of the two regression coefficients. For example, if X predicts Y 
and Y predicts Z, then the indirect effect of X on Z equals the product of the two 
regression coefficients (X on Y and Y on Z). Lastly, to ensure the validity of our SEM 
results, we checked our results using negative binomial regression analysis with 
clustered robust standard errors. Analyses were performed using Mplus 7. 
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Results  
 
Study Population  
 
The final sample included 481 physicians with complete information.  Table 5 
provides descriptive statistics for the entire sample. Notably, 74% were male, 75% were 
White non-Hispanic, and their mean age was 53 years; they have been in practice a 
mean of 26 years. The vast majority practiced in group practices and trained in the U.S; 
72% were oncology-based specialists, 10% were surgeons, and 18% reported another 
medical specialty (e.g., gynecology, pediatrics, internal medicine). Physicians enrolled a 
mean of 5 patients in 2011 (range: 0-62); approximately 40% of physicians enrolled no 
patients in the 9-month reporting period. 
SEM Analysis  
 
The fit statistics and modification indices for the fixed parameters of the original 
model tested in Figure 2 suggested that we re-specify the model to improve fit (CFI = 
0.648; TLI = 0.560; RMSEA = 0.067; SRMR = 0.061). Therefore, we added seven post-
hoc modifications that were theoretically justified and improved model fit. Figure 3 
presents the final model with all post hoc modifications and standardized estimates. For 
these modifications, we allowed the error terms of the following measures to co-vary 
higher than with other variables. For example, the percentage of doctors supported in 
screening and enrolling patients, likely share common variation that is not explained by 
any of the proposed relationships in the model. 
1) Peer-usage with the outcome: Peer-usage is based on the individual physicians’ 
enrollment within a specific CCOP. We co-varied the error terms as they likely 
share common variation that is not explained by relationships in the model.  
 41 
 
2) The percentage of doctors supported in screening and enrolling patients: The 
same support staff generally preform both functions within a CCOP.  
3) Trainings offered with the percentage doctors who are supported in screening and 
enrolling patients: The number of trainings offered relates to the number of 
support staff available. 
4) Incentives with expectations for enrollment: CCOPs that provide incentives may 
also be more likely to have expectations for enrollment.  
5) Affect with values: Providers who believe that trials explore important issue are 
also likely to value participating. 
6) Belief that trials are too complex with belief that trials exclude too many patients: 
These relate to an overall negative view of CCOP and may discourage 
participation. 
7) Affect with whether physicians believe trials exclude too many patients: Providers 
who report that trials are important are less likely to think they exclude too many 
patients.  
With the addition of each co-variance, we tested the baseline model against the new 
model for improved model fit. Overall, we achieved a final well-fitting model (CFI = 
0.936; TLI = 0.914; RMSEA = 0.030; SRMR = 0.046) (Figure 3). 
In general, standardized effects of less than 0.10 constitute a small effect; values 
greater than 0.30 indicate a medium effect; and values greater than 0.50 indicate a 
large effect (Suhr, 2006). Overall the effect sizes were fairly small for the latent 
constructs of organizational context and individual attitudes, which had significant 
positive direct effects on the outcome. For example, the direct effect of organizational 
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context on enrollment was β=0.19 (p=0.02) and for physician attitudes it was β=0.13 
(p=0.04). In addition, physician’s CCOP PI status, age, and non-oncologist specialty 
also had significant direct effects on enrollment. The most significant positive direct 
effect was whether the physician was the PI (β=0.35; p<0.00). Physician age (β= -0.27; 
p=0.02) and non-oncology specialty (β= -0.14; p=0.03) had significant negative direct 
effects on enrollment.  
There was no evidence, however, that organizational context or any physician 
individual characteristics significantly influenced accrual through their effects on 
physician attitudes.  Finally, training location, practice location, and physicians who are 
surgeons, hematologists, and radiological oncologists (compared to non-specialized 
oncologists) did not directly affect enrollment. Overall our model explained 21% of the 
variance in patient enrollment.  The robustness check of our SEM results using negative 
binomial regression analysis with clustered robust standard errors confirmed our main 
findings that both organizational context and attitudes were significantly associated with 
patient enrollment, along with physician status as the CCOP PI and medical specialty.  
Discussion  
 
We hypothesized that organizational contextual factors and physicians’ attitudes 
and individual characteristics would directly and indirectly (through attitudes) be 
associated with their enrollment of patients in NCI-sponsored cancer clinical trials. This 
hypothesis was partially supported as organizational context and physician attitudes 
directly influenced enrollment; however, there were no indirect effects on enrollment 
through attitudes. Attitudes impacted enrollment as physicians who: viewed participation 
as more useful and easy, had individual values aligned with CCOP goals, and had more 
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positive feelings were more active in enrolling patients in trials. This finding highlights 
the importance of recruiting physicians for volunteer research programs who value 
participating in clinical trials, find participating in trials important, and feel they are able 
to do so. Recruiting physicians whose attitudes align with the program’s goals is 
especially important for community sites interested in participating in the new NCORP. 
Interestingly, organizational context did not predict physicians’ attitudes. Changes in 
organizational context may influence overall enrollment of patients as a supportive 
environment assists with accrual efforts, but these contextual factors do not appear to 
impact the attitudes of physicians. This finding further supports recruiting physicians 
with positive attitudes towards participating in clinical research. 
In addition, as hypothesized, contextual factors made a difference. Specifically, 
organizations that provided support for physicians to consent and enroll patients, 
offered incentives for enrollment, and mandated expectations for enrollment also 
increased physician enrollment, perhaps due to a strong sense of organizational 
commitment and social norms. Therefore CCOPs or other voluntary research programs 
might encourage physicians to actively participate and enroll patients. Program 
administrators should consider providing support for physicians’ research activities, 
such as staff to help consent and enroll patients, incentives for enrollment goals (e.g., 
small tokens of appreciation, public acknowledgment), and trainings to learn about 
latest developments in research. Such strategies may not directly change physician 
attitudes, but may provide a supportive organizational context to encourage active 
physician participation in recruiting patients.  
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We were surprised that organizational context did not have an indirect effect on 
enrollment by influencing physicians’ attitudes towards clinical trials. Perhaps 
physicians’ attitudes were not a significant mediator of organizational context because 
physicians elect to participate in CCOP. Although implementation of some innovations 
in healthcare may be mandated, clinical trial participation, however, is not required.  It 
may be that, specific organizational contextual factors do not influence attitudes among 
physicians who have already agreed to participate and recruit patients to clinical trials. 
Organizational context may shape attitudes towards participation in other types of 
settings where participation or implementation of a specific innovation is mandatory and 
attitudes would likely be more fluid. Therefore, organizational context would have more 
of an opportunity to determine attitudes towards participation. 
In addition, four physician characteristics also significantly effected enrollment.  
Physician status (i.e., CCOP PI or not) was the strongest predictor. PIs are more likely 
than non-PIs to be committed to the CCOP and feel obligated to set a “good example” 
for their colleagues. PIs may also be more familiar with available trial protocols and 
receive greater assistance from support staff to consent and enroll patients. A strong 
negative predictor of enrollment was whether the physician was a non-oncology 
specialist. One reason may be that non-oncologists feel less comfortable and/or familiar 
with cancer protocols than oncologists. In addition, both physician age and tenure had 
significant total effects on outcome.  
We were surprised that practice location, foreign medical training, and medical 
specialty (with the exception of non-oncology) did not impact enrollment.  Although none 
of the previous studies exclusively examined enrollment among CCOP physicians, past 
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studies found that practice type (i.e., office-based practice compared to hospital based 
practice) and medical specialty (i.e., medical oncologists compared to radiation 
oncologists) increased physician enrollment of patients while foreign-trained oncologists 
enrolled fewer patients. In our study, practicing at a hospital or as a solo physician 
(compared to a group practice) may not have had a significant effect because it was 
difficult to discern a physician’s main practice location. In addition, many CCOP 
physicians travel between different offices, which may make their primary location less 
relevant. We suspect that foreign medical training did not impact enrollment because we 
could not determine how long physicians had been practicing in the U.S., which is likely 
a more relevant predictor of enrollment than training location. In addition, medical 
specialty may not be as influential on enrollment as there are an abundance of types of 
cancer clinical trials, including protocols for surgery and radiological interventions. 
Therefore all cancer-related specialties are comfortable and willing to enroll patients in 
cancer trials.    
Limitations  
There are several limitations of our study. First, we only included physicians who 
participate in CCOPs.  These physicians have already agreed at least on some level to 
participate in CCOP. Therefore our findings suggest the organizational and individual 
factors that are most relevant to encourage active participation in CCOP. It is important 
to note, however, that many organizational strategies (e.g., recognition of high 
achievers, expectations for enrollment) could be implemented by diverse organizations 
to increase physician participation in clinical research. Second, we are unable to 
account for variation in the number of potentially eligible patients physicians see. 
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Therefore, we were unable to distinguish physicians failing to offer a cancer clinical trial 
from patients’ refusal to enroll. We also lacked the data to incorporate patient-level 
characteristics in the analyses. We cannot account for variations in patients’ cancer 
stage, co-morbidities, age, or any other factors that may determine eligibility. Ultimately 
patients are the final decision makers regarding their participation in a cancer clinical 
trial. However, given that 75% of patients agree to enroll if offered we do not believe this 
to be a significant limitation of this study (Albrecht et al., 2008).  Third, given that we 
were only able to explain 21% of the variance in enrollment, we were also limited in the 
data that was available to examine individual physician enrollment. Future studies may 
want to consider including additional factors, such as patient-level characteristics in the 
model to increase the amount of variation explained. In addition, more information on 
physician behaviors and personality traits (e.g., personal disposition to innovativeness, 
goal-orientation) may also help to explain variance in enrollment in cancer clinical trials.   
We believe this study extends the literature in several important ways. First, it is 
the first study to evaluate physician-level predictors of their success in enrolling patients 
in CCOP cancer clinical trials. Second, it provides the basis of physician-directed 
strategies that may effectively promote enrollment of patients in cancer clinical trials. By 
expanding the number of patients involved in cancer clinical trials, we can accelerate 
the pace in which we identify promising innovative therapies and novel interventions 
that can ultimately improve the outcomes of cancer patients. 
Conclusions  
The findings from this study are important for program administrators looking to 
increase volunteer physician participation in clinical research as well for new NCORP 
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program sites. Our results suggest two strategies to increase participation. The first is to 
ensure physicians attitudes and values align with the programmatic goals. For example, 
recruiting physicians who value participating in clinical trials, find participating in trials 
important, and feel they are able to do so is a key determinant of a program’s success. 
Recruitment of physicians whose values align with program goals is especially 
important given that CCOP organizational context did influence attitudes towards 
participation. Second, program administrators should consider providing support for 
physicians’ research activities, such as staff to help consent and enroll patients, 
incentives for enrollment goals (e.g., small tokens of appreciation, public 
acknowledgment), and trainings to learn about latest developments in research. Such 
strategies may not directly change physician attitudes, but may provide a supportive 
organizational context to encourage active physician participation in recruiting patients.  
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Table 4: Overview of Variables and Measures for Aim 1 
  
Model&Construct& Variable& Measure& Measure&Type& Data&Source&
Innovation(Acceptance( Enrollment No.(of(patients(enrolled(in(NCI7sponsored(cancer(
clinical(trials(in(2011
Continuous( CCOP(Progress(Reports(
Attitudes( Affect NCI7sponsored(trials(explore(clinical(issues(that(are(
important(in(my(practice(
Continuous( CCOP7Affiliated(
Physician(Survey
Attitudes( Beliefs:(Exclude(
Patients(
NCI7sponsored(trials(exclude(too(many(patients( Continuous( CCOP7Affiliated(
Physician(Survey
Attitudes( Beliefs:(Trials(Complex NCI7sponsored(trials(are(too(complex(to(do(in(my(
practice(
Continuous( CCOP7Affiliated(
Physician(Survey
Attitudes( Personal(Values( I(value(participating(in(NCI7sponsored(clinical(trials Continuous(
CCOP7Affiliated(
Physician(Survey
Organizational(Context( Training(
CCOP(sponsor(any(events(where(physicians(could(
learn(about(the(latest(developments(in(cancer(
research,(treatment,(prevention,(or(control?(
Binary:(0(=(N;(1=Y
CCOP(Administrator(
Survey(
Organizational(Context( Support:(Screening(
Proportion(of(physicians(that(have(CCOP(staff(
members(routinely(screen(patient(charts(for(
potentially(eligible(patients
Continuous( CCOP(Administrator(
Survey(
Organizational(Context( Support:(Enrolling
Proportion(of(physicians(that(have(CCOP(staff(
members(routinely(assist(with(enrollment Continuous(
CCOP(Administrator(
Survey(
Organizational(Context( Incentives(
CCOP(provide(some(form(of(recognition(to(Type7A(
physicians(with(high(levels(of(accrual(to(NCI7
sponsored(trials?
Binary:(0(=(N;(1=Y
CCOP(Administrator(
Survey(
Organizational(Context( Peer(Usage Average(no.(of(patients(enrolled(in(NCI7sponsored(
clinical(trials(by(physicians(in(CCOP
Continuous( CCOP(Progress(Reports(
Organizational(Context( Expectations(
CCOP(expect(Type7A(physicians(to(enroll(a(minimum(
no.(of(patients(in(NCI7sponsored(trials? Binary:(0(=(N;(1=Y
CCOP(Administrator(
Survey(
Personal(Characteristics Age The(current(year(minus(the(physicians’(year(of(birth Continuous( AMA(Provider(Masterfile
Personal(Characteristics Practice(Type( Indicator(of(present(primary(employment(
arrangement((e.g.,(solo,(group,(hospital)
Categorical AMA(Provider(Masterfile
Personal(Characteristics U.S(Trained Indicator(if(physician(trained(in(the(U.S. Binary:(0(=(N;(1=Y AMA(Provider(Masterfile
Personal(Characteristics PI Please(indicate(the(PI(of(the(CCOP Binary:(0(=(N;(1=Y CCOP(Progress(Reports(
Personal(Characteristics Medical(Specialty( Indicator(of(physician(self7designated(primary(
medical(specialty(
Categorical AMA(Provider(Masterfile
Personal(Characteristics Tenure No.(of(years(since(graduated(medical(school Continuous( AMA(Provider(Masterfile
Table&4:&Overview&of&Variables&and&Measures&for&Aim&1&
&Outcome&Variable&
Predictor&Variables&
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CCOP$Survey$Respondents$n=481
Mean%or%Proportion%of%Sample% Range
2011%Patient%%Enrollment%
4.7*%
(8.1)
%0,%62
Gender
!!!Male 74%
!!!Female! 26%
Race
!!!White 75%
!!!Asian 15%
!!!African2American! 1%
!!Other 9%
Attitudes(
Affect 4.6
(0.7)
2,5
Beliefs:$Exclude$Pts. 3.4%
(1.2)
1,5
Beliefs:$Complexity$of$Trials 2.4
(1.2)
1,5
Values$ 4.7
(0.6)
1,5
Personal(Characteristics(
Age 52.6
(9.8)
34,82
Practice$Type
!!!Group!Practice 78%
%%%Hospital2Based 12%
!!!Solo!Practice 4%
!!Other/None!Listed 6%
Training$Location$
!!!U.S!Trained 80%
!!!Non!U.S!Trained 20%
Tenure$(Yrs.$In$Practice) 25.7
(10.1)
%8,%57
Medical$Specialty$
!!!Hematology!Oncology 40%
!!!Radiation!Oncology 21%
!!!Other!Specialty 18%
!!!Medical!Oncology 11%*
!!!Surgery! 10%*
Principal$Investigator$ 9%
*Indicates%significant%difference%between%survey%respondents%and%nonLsurvey%respondents%
Other!race%includes%American%Indian,%Native%Hawaiian/Pacific%Islander,%More%than%one%race,%or%unknown
Hematology!oncology%includes%blood%banking,%hematology%oncology,%hematology
Radiation!Oncology%includes%diagnostic%radiology,%nuclear%medicine,%radiation%oncology,%radiology,%vascular%and%interventional%radiology
Other!specialist%includes%general%practice,%gynecological%oncology,%%pediatrics,%pediatric%hematology,%cardiovascular%disease%etc.%
Surgery%includes%colon%and%rectal%surgery,%critical%care%sugary,%general%surgery,%neurological%surgery,%surgical%oncology,%urological%surgery%etc.%
Descriptive(Variables
Outcome(
Table$5:$Descriptive$Statistics$Aim$1$Physician$Level$Variables$
Standard%deviations%in%parentheses%
Variables(included(in(Model(
Table 5: Descriptive Statistics Aim 1 Physician Level Variables 
 50 
 
Figure 1: Individual Innovation Acceptance in Organizations 
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Figure 2: Tested Model of Individual Innovation Acceptance in Organizations 
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CHAPTER 5: THE MISSING LINK: A TEST OF KLEIN AND SORRA’S PROPOSED 
RELATIONSHIP BETWEEN IMPLEMENTATION CLIMATE, INNOVATION-VALUES 
FIT AND IMPLEMENTATION EFFECTIVENESS 
 
Overview 
 
Klein and Sorra’s theory of innovation implementation suggests that the 
effectiveness of implementing an innovation results from both a climate that supports, 
rewards, and expects implementation as well as from the fit between the innovation and 
the intended users’ values. Although the authors propose that innovation-values fit 
moderates the effect of implementation climate on implementation effectiveness, this 
relationship is rarely tested in practice. In addition, most of the evidence supporting the 
use of the theory in health and human services research is from qualitative studies, 
while most of the quantitative tests of the theory occur in the computing or information 
systems environment.  
Therefore, the goal of this study is to quantitatively test the proposed relationship 
in which innovation-values fit moderates the effect of implementation climate on 
implementation effectiveness in a health services setting. We tested the theory of 
innovation implementation using structural equation modeling (SEM) among 481 
physician participants in the National Cancer Institute’s Community Clinical Oncology 
Program (CCOP). The data sources included the CCOP Annual Progress Reports, a 
survey of CCOP physician participants, and the American Medical Association 
Physician Masterfile. Overall the hypothesized SEM model fit well. Our results 
demonstrated that both implementation climate and innovation-values fit were 
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significantly associated with implementation effectiveness among CCOP physicians 
(p=<0.05). In addition, including innovation-values fit as a moderator improved the 
overall fit of our SEM. The moderator explained 2.6% of the variation in implementation 
effectiveness and approached statistical significance (p=0.06).  
Our study advances both innovation implementation theory as well as clinical 
practice. The results of this study extend the scientific literature by not only empirically 
examining the theory of innovation implementation in a health services setting, but also 
by testing whether innovation-values fit moderates the effect of implementation climate 
on implementation effectiveness, which has yet to be fully explored. Practically, CCOP 
administrators or other program directors looking to increase physician participation in 
clinical research should foster a strong implementation climate to encourage enrollment, 
as in this setting innovation-values fit did not statistically strengthen the relationship 
between implementation climate and implementation effectiveness.  
Background   
 Implementation effectiveness, or the consistency and quality of organizational 
members’ use of a specific innovation, is important because it is the key determinant 
regarding the benefits an organization may receive by implementing a given innovation 
(e.g., increased profitability, employee morale, productivity) (Klein & Sorra, 1996).  
Although several conceptual frameworks highlight innovation adoption and/or the 
effectiveness of the innovation itself, few theories focus on explaining the effectiveness 
of the implementation process (Davies et al., 2010) (Whitman, 2009) (VA, 2009). Klein 
and Sorra’s theory of innovation implementation suggests that implementation 
effectiveness results from both a climate that encourages implementation, as well as the 
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fit between the innovation and the organizational members’ values (Klein & Sorra, 
1996). Their theory is unique in that it not only explains implementation effectiveness, 
but it also highlights the effectiveness of the innovation itself. Although the theory 
originated in manufacturing, it has become a more common approach to address 
innovation implementation in the field of health services research (Weiner et al., 2011).   
One of the issues associated with using the theory of innovation implementation 
in health services research is that most evidence supporting its use in this context is 
qualitative in nature (Weiner et al., 2011) (Weiner et al., 2012) (Teal et al., 2012) 
(Damschroder et al., 2009) (Weiner et al., 2009) (Helfrich et al., 2007). Although 
important, qualitative studies tend to utilize smaller sample sizes, have limited external 
generalizability, and present challenges in standardizing the measurement of key 
constructs. In terms of quantitative evidence, the majority of supportive evidence is from 
studies examining the effectiveness of technology implementation among company 
employees in information systems and computing organizations (Holahan et al., 2004) 
(Dong et al., 2008) (Klein et al., 2001) (Osei-Bryson et al., 2008). These settings are 
difficult to compare to healthcare because: (1) physicians experience greater 
professional autonomy, and (2) the process of implementing computing technology may 
differ from delivering clinical care.  
A second outstanding issue surrounding the use of the theory of innovation 
implementation in health services research is that the main relationship between 
implementation climate and innovation-values fit has not been empirically tested. Klein 
and Sorra propose that innovation-values fit (between the innovation and the 
organizational members’ values) moderates or strengthen the effect of perceptions of 
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implementation climate on implementation effectiveness. So, a strong sense of 
innovation-values fit will intensify the relationship between implementation climate and 
implementation effectiveness (Klein & Sorra, 1996).  Prior research testing the theory of 
innovation implementation has included both concepts, but whether innovation-values fit 
moderates the effect of implementation climate on implementation effectiveness has yet 
to be examined (Holahan et al., 2004) (Dong et al., 2008) (Klein et al., 2001) (Osei-
Bryson et al., 2008). The lack of current studies examining innovation-values fit as a 
moderator may be attributable to the fact that the figure included in Klein and Sorra’s 
seminal article detailing the theory does not depict this relationship (Figure 4) (Klein & 
Sorra, 1996). It is important to empirically examine innovation-values fit as a moderator 
between implementation climate and implementation effectiveness to provide further 
evidence on the utility of using this theory in health services research and to better 
understand the proposed relationship between implementation climate and innovation-
values fit.  
Therefore, the goal of this study is to draw on Klein and Sorra’s theory to test 
whether innovation-values fit moderates the effect of implementation climate on 
implementation effectiveness in a health services context. We used structural equation 
modeling (SEM) to examine implementation effectiveness among physician participants 
in the National Cancer Institute’s (NCI) Community Clinical Oncology Program (CCOP), 
a national provider-based research network aimed at engaging community physicians in 
NCI-sponsored clinical trials in order to advance scientific findings and facilitate the 
translation of research results into practice (Comis et al., 2009). The findings of this 
study extend the current literature by testing the proposed relationship between 
 57 
 
implementation climate and innovation-values fit. Our results also suggest that potential 
administrative changes in the CCOP network and other provider-based research 
networks can lead to an increase in the enrollment of patients in cancer clinical trials.  
Methods  
Theoretical Framework  
Using Klein and Sorra’s theory of innovation implementation (1996), we sought to 
test whether innovation-values fit moderates the effect of perceptions of implementation 
climate on implementation effectiveness (Figure 5). The authors propose that 
implementation effectiveness results from both a climate for implementation, or the 
extent to which the use of a specific innovation is rewarded, supported, and expected 
within an organization, and innovation-values fit, or the extent to which intended users 
perceive that the innovation is consistent with their current values (Klein & Sorra, 1996). 
Klein and Sorra suggest that all three of these constructs should be assessed at the 
organizational level (1996).  For example, they propose that innovation-values fit and 
implementation climate are homogenous constructs composed of organizational 
members’ shared perceptions, and are therefore not based on specific individual 
perceptions of climate or values fit (Klein & Sorra, 1996). In addition, they indicate that 
implementation effectiveness represents the overall consistency and quality of an 
organization’s innovation use (Klein & Sorra, 1996) (Weiner et al., 2011). In practice, 
however, the theory has been empirically tested at both the organizational and 
individual levels (Holahan et al., 2004) (Dong et al., 2008) (Klein et al., 2001) (Osei-
Bryson et al., 2008). 
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In this study, we were most interested in examining individual physician 
participation in CCOP because of the significant variation that occurs in enrolling 
patients in cancer clinical trials. Although all physicians agree to participate in CCOP at 
some level, the number of patients enrolled by CCOP physicians in 2011 ranged from 0 
to 88 patients per physician, with over 40% of physician enrolling zero patients. In 
testing an organizational-level theory at the individual level, researchers should not 
assume that the same theoretical relationships apply (Klein & Kozlowski, 2000). 
Modifications to the model may be needed to ensure that the constructs are relevant at 
the individual level. For example, in this study we believed that individual physician 
characteristics (e.g., age, medical specialty, status as the CCOP Principal Investigator 
(PI)) would also influence implementation effectiveness. We modified the original model 
to include these physician characteristics in order to test the model among individual 
physicians (Figure 6). 
Specifically, we propose that a strong implementation climate would lead to 
higher patient enrollment among physicians because perceptions that a CCOP institutes 
accrual expectations, provides support for the enrollment of patients, as well as 
recognizes enrollment efforts should encourage physicians to enroll more patients in 
cancer clinical trials. A strong implementation climate would ensure physicians have the 
skill and support needed to enroll patients, incentives to participate are in place, and 
obstacles to enroll patients are limited.  
Hypothesis 1: Implementation climate will have a direct effect on 
implementation effectiveness.  
 
The relationship between climate and implementation effectiveness should be 
strengthened if physicians also perceived that participating in clinical research aligned 
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with their personal values, felt participating was important, and wanted to enroll patients. 
For example, when innovation-values fit is good (i.e., physicians view CCOP 
participation as highly congruent with their values), physicians should be committed to 
participating in CCOP. If the CCOP’s climate also encourages implementation, 
enrollment should be greater as physicians are also skilled and encouraged to enroll 
patients. If the climate is weak, however, enrollment may be more sporadic as although 
physicians are committed to clinical research, the CCOP climate is not providing the 
skills and incentives needed to enroll patients. However, when innovation-values fit is 
poor (i.e., physicians regard CCOP participating as highly in congruent with their 
values), physicians will likely resist active participation in CCOP by not enrolling 
patients, regardless of implementation climate. A strong climate would make 
participating in CCOP easier, but unless physicians are committed to enrolling patients, 
they are unlikely to do so.  
Hypothesis 2: Innovation-values fit will moderate the relationship between 
implementation climate and implementation effectiveness  
 
As discussed, we also included physician level variables in the model. We propose that 
physician enrollment may vary based on the physician’s status as the CCOP PI, age, 
years in practice, medical specialty, training location, and practice location (Comis et al., 
2009) (Jacobs et al., 2014). These individual characteristics may impact a physician’s 
ability and desire to enroll patients in trials. For example, the CCOP PI would likely be 
more inclined to participate as they want to set a good example for other CCOP 
physicians regardless of their perceptions of climate, while non-oncology specialists 
may feel less comfortable with cancer protocols and would enroll fewer patients per 
year regardless of implementation climate or innovation-values fit. In addition, older 
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physicians and those that train outside of the United States should be included as they 
may negatively influence enrollment while physicians that practice in a hospital setting 
may have more access to resources and thus practice location may positively influence 
enrollment. 
Hypothesis 3: Physician characteristics will have a direct effect on 
implementation effectiveness 
Study Setting and Sample  
 
The study was conducted in NCI’s CCOP network. The CCOP network was 
created in 1983 with the goals of advancing the evidence-base by conducting research 
in clinical settings where most people receive their care, and translating results into 
better care (Kaluzny et al., 1994) (Kaluzny et al., 1995) (Minasian et al., 2010) 
(Carpenter et al., 2012) (Weiner et al., 2012) (Jacobs et al., 2013). The CCOP network 
is a joint venture between NCI’s Division of Cancer Prevention (NCI/DCP), selected 
cancer centers and clinical cooperative groups (CCOP research bases), and 
community-based physicians and hospitals (CCOP organizations). NCI/DCP provides 
overall direction and funding for community hospitals and physician practices to 
participate in clinical trials while CCOP research bases design clinical trials and CCOP 
organizations assist with patient enrollment, data collection, and dissemination of study 
findings (Kaluzny et al., 1994) (Kaluzny et al., 1995) (Minasian et al., 2010) (Carpenter 
et al., 2012) (Weiner et al., 2012) (Jacobs et al., 2013). In 2011, when the study was 
conducted, the CCOP network consisted of 47 CCOP organizations in 28 states, the 
District of Columbia, and Puerto Rico and included 400 hospitals and 3,520 community 
physicians. CCOP organizations consisted on average of 10 community hospitals or 
physician practices and 48 physicians. Our specific sample included 485 CCOP 
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physicians who responded to the 2011 CCOP-Affiliated Physician Survey, described in 
detail below.  
In FY 2012 the CCOP budget totaled $87.4 million. The median CCOP 
organization award was $705,000. NCI funds CCOP organizations through a 
cooperative agreement whereby participating organizations are expected to share the 
costs with NCI. Continued funding depends on CCOP organizations’ meeting clinical 
trial accrual goals set by NCI. CCOP organizations are generally composed of a 
physician CCOP PI who provides local program leadership, a team of support staff, as 
well as affiliated physicians who enroll patients in NCI-sponsored cancer clinical trials 
(Weiner et al., 2011) (Teal et al., 2012). CCOP staff members typically include an 
associate PI, program administrators, research nurses or clinical research associates, 
data managers, and regulatory specialists who together coordinate the review and 
selection of clinical trial protocols for the CCOP, disseminate any trial protocol updates, 
collect study data, and assist affiliated physicians with enrollment (Teal et al., 2012). 
CCOP-affiliated physicians include specialized oncologists (e.g., hematological, surgical 
and radiation oncologists), general medical oncologists, and other medical specialists 
(e.g., urologists, gynecologists, and gastroenterologists). 
Data Sources  
 
The data for this cross-sectional study were obtained from three sources. First, 
this study utilizes the 2011 CCOP Annual Progress Reports submitted in March 2012, 
which cover the period from June 1, 2011 to February 29, 2012. Each March, every 
CCOP submits a progress report to NCI detailing the previous nine-month’s research 
and enrollment activities. The report includes standardized questions regarding the 
 62 
 
allocation of CCOP resources, staffing assignments, total cancer patient volume, the 
number of open cancer clinical trials, the total number of patients each CCOP enrolls, 
as well as the total number of patients each individual CCOP-affiliated physician enrolls.  
Second, we used the 2011 CCOP Physician Survey, which was administered as 
part of a larger NCI-funded-study (5R01CA124402). The goal of this survey was to learn 
more about physician participation in the CCOP program. The physician survey 
included specific questions regarding physicians’ perceptions regarding expectations for 
enrollment, research support provided by the CCOP, ability to provide input, how well 
they are kept informed of CCOP activities, recognition received from the CCOP, as well 
as personal beliefs, attitudes, and values regarding the importance of cancer clinical 
trials. These surveys specifically supplied data on CCOP physicians’ perceptions of 
innovation climate as well as their perceptions of innovation-values fit.  
The sampling frame included all CCOP-affiliated physicians eligible to accrue 
patients to clinical trials. Between October 2011 and January 2012, we surveyed 817 
physicians using a random sample stratified across all 47 CCOPs. On average, 17 
physicians were surveyed per CCOP, and 10 physicians responded per CCOP 
organization. One week after sending potential respondents a postcard announcing the 
survey and highlighting its importance to NCI, physicians were sent a cover letter 
explaining the goals of the survey, the survey itself, a self-addressed and stamped 
return envelope, and a $50 Visa gift card as an incentive to complete the survey. 
Physicians were also able to complete the survey online via a unique access code 
provided in the mailings. A thank you or reminder postcard was then sent the following 
week. Approximately three weeks after the first mailing, non-respondents received a 
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second copy of the survey, cover letter, and return envelope. Lastly, we contacted 
CCOP PIs and CCOP Administrators to email the non-responding physicians affiliated 
with their CCOP requesting them to complete the survey.  
The 2012 American Medical Association (AMA) Physician Masterfile provided 
data for the individual physician control variables. Established in 1906, the Physician 
Masterfile includes current and historical data for more than 1.4 million physicians, 
residents, and medical students in the U.S.. The AMA Physician Masterfile contains 
demographic information, such as age and gender, as well as specialty, experience, 
and medical school training and residency.  
Measures  
 
The measures for this study included: implementation effectiveness, questions 
relating to perceptions of implementation climate, questions concerning perceptions of 
innovation-values fit, and physician characteristics. The outcome, implementation 
effectiveness, consistency and quality of organizational members’ use of a specific 
innovation, was assessed as the number of patients that each individual physician 
enrolled in NCI-sponsored cancer clinical trials in 2011.  
The implementation climate construct included six questions from the CCOP 
Physician Survey that were based on the measurement approached outlined in the 
literature and were consistent with how prior studies have addressed implementation 
climate (Klein & Sorra, 1996) (Weiner et al., 2011) (Weiner et al., 2012)  (Weiner et al., 
2009) (Helfrich et al., 2007) (Teal et al., 2012) (Holahan et al., 2004) (Dong et al., 2008) 
(Klein et al., 2001) (Osei-Bryson et al., 2008). The items were descriptive (rather than 
evaluative) and were direct measures of climate perceptions (rather than indirect 
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measures of specific implementation policies and practices). There were two questions 
for each of the three dimensions of implementation climate, expectations, support, and 
rewards (Weiner et al., 2011). Two questions addressed physician expectations and 
asked physicians if: 1) they are expected to enroll a certain number of patients in trials 
and 2) if they are expected to help the CCOP meet its patient enrollment goals. Two 
questions addressed whether physicians get the support they need to: 1) identify 
potentially eligible patients and 2) enroll patients in trials. Lastly, two questions 
addressed rewards by asking if physicians receive: 1) recognition and 2) appreciation 
when they enroll patients in trials. For all questions physicians were able to select 
disagree, somewhat disagree, neither agree nor disagree, somewhat agree, or agree 
The innovations-value fit construct included four questions from the CCOP 
Physician Survey. We also developed these items based on the prior literature (Klein & 
Sorra, 1996) (Weiner et al., 2011). Questions asked physicians if they wanted to offer 
trials to patients, if participating in clinical trials was important, if clinical trials explore 
important clinical issues, and lastly if they valued participating in clinical trials. 
Physicians were also able to select disagree, somewhat disagree, neither agree nor 
disagree, somewhat agree, or agree.  
Lastly, we also included physician characteristics such as age, if they trained in 
the United States, medical specialty, and whether or not the physician was the CCOP 
PI. We also included the practice arrangement (i.e., hospital-, group-, or solo- based) 
and how long the physician had been in clinical practice.  
Data Analysis  
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SEM with maximum likelihood estimation was used to test the effect of 
innovation-value fit as a moderator between the implementation climate and 
implementation effectiveness. SEM is composed of multivariate regression models and 
can be used to estimate proposed causal relationships (Norman & Streiner, 2003) (Hox 
& Bechger, 2007) (Schreiber et al., 2006). We selected SEM because it allowed us to 
test for constructs that are not directly assessed, but are instead composed of observed 
indicators representing the constructs of interest (e.g., innovation-values fit, 
implementation climate).   
The goal of SEM is to achieve a well-fitting model. The proposed model should 
be based on theory (Muthen, 2012) (Mooijaart & Satorra, 2009) (Klein & Moosbrugger, 
2000). Therefore, based on our prior knowledge of implementation climate, we believed 
that the two questions that composed each of the three components of implementation 
climate (i.e., support, reward, expectations) would co-vary higher than with questions 
representing the other two components. For example, the two questions that compose 
expectations, physicians are expected to enroll a certain number of patients and 
physicians are expected to help the CCOP meet its goals, likely share common 
variation that is not explained by any of the proposed relationships in the model. 
Therefore we decided a priori to add three covariances, one between each of the two 
questions that address expectations, support, and rewards. We then used confirmatory 
SEM to test the hypothesized pathways among implementation factors represented in 
Figure 6 by comparing how well this proposed structure fits the observed data. 
Specifically, to test for a moderated relationship using SEM, we created an 
interaction between implementation climate and the moderator, innovation-values fit. 
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We then followed the procedure as outlined by Muthén to evaluate models with latent 
variables interactions (Muthén, 2012). To test the significance of the moderation effect, 
we had to compare differences in model fit between the SEM with and without the 
moderation construct. We first fit the model without the interaction term and obtained a 
well-fitting model in terms of general fit statistics. Next, we added the interaction term to 
the model, and looked for improvements in model fit by comparing the difference 
between models using a Likelihood-Ratio (LR) test (Muthén, 2012) (Mooijaart & Satorra, 
2009) (Klein & Moosbrugger, 2000).  
We evaluated our final well-fitting model without the latent variable interaction 
using the Comparative Fit Index (CFI), the Tucker-Lewis Index (TLI), the root mean 
square error of approximation (RMSEA), and the standardized root mean squared 
residuals (SRMR). CFI and TLI values range from 0 to 1, with values greater than 0.90 
representing adequate fit (Norman & Streiner, 2003) (Hox & Bechger, 2007) (Schreiber 
et al., 2006). Ideal RMSEA values should be less than 0.06 with an upper bound of the 
confidence interval less than 0.1 and SRMR should have values less than 0.08 (Norman 
& Streiner, 2003) (Hox & Bechger, 2007) (Schreiber et al., 2006). We then evaluated 
the final model with the interaction term by testing the significance of all standardized 
estimates and calculating the overall variance explained in the outcome (R2), 
implementation effectiveness, as well as the percentage of variance explained by the 
latent variable interaction term. Lastly, to ensure the validity of our SEM results, we 
checked our results using negative binomial regression analysis with clustered robust 
standard errors. Analyses were performed using Mplus 7.  
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Results  
 
Study Sample  
 
The final sample for this study was comprised of 481 physicians with complete 
data who responded to the 2011 CCOP-Affiliated Physician Survey (Table 6).  The 
majority of the sample was male (74%), White non-Hispanic (75%), with a mean age of 
52.6 years. In addition, the majority of respondents practiced in a group practice (78%), 
trained in the U.S. (80%), and had been in practice on average almost 26 years. Over 
70% were oncology-based specialists, 9% were the PI of the CCOP and physicians on 
average enrolled almost five patients in 2011.  
The only significant (p<0.05) differences between survey responders and non-
responders were that responders enrolled more patients per year (4.7 versus 3.4), were 
more likely to be a surgeon (10% versus 5%), and were less likely to be a non-
specialized medical oncologist (11% versus 24%).   There were no significant 
differences between respondents and non-respondents regarding gender, race, age, 
practice type, training location, and tenure. 
Structural Equation Modeling  
 
The fit statistics for the model without the interaction term as well as the 
modification indices did not indicate that we needed to re-specify the model or make 
any further adjustments (CFI = 0.967; TLI = 0.961; RMSEA = 0.032; SRMR = 0.051). 
Figure 7 provides a graphic version of the final SEM result. Standardized and 
unstandardized estimates are also provided in Table 7. The results of the SEM that 
included the interaction with the modifier (innovation-values fit) indicated that model fit 
significantly improved (p<0.001). Overall, we explained approximately 31% of the total 
 68 
 
variation in the outcome, implementation effectiveness. In addition, we found that 3% of 
this variance is attributable to the interaction with innovation-values fit.  
The latent constructs of implementation climate and innovation-values fit had 
significant independent effects on implementation effectiveness. Although the 
interaction accounted for 3% of the overall variance in implementation effectiveness, the 
interaction term is on the border of being significant (p=0.06). Therefore, innovation-
values fit did not statistically strengthen the relationship between implementation climate 
and implementation effectiveness in this setting. The robustness check of our SEM 
results using negative binomial regression confirmed our main findings that 
implementation climate and innovation-values fit alone were each significantly 
associated with implementation effectiveness; however, adding in the interaction term 
caused all of the predictors to no longer be significant. 
Discussion  
Overall Significance  
 The findings from this study have both scientific implications for innovation 
implementation theory, as well as practical implications for CCOPs and other programs 
looking to increase volunteer physician participation. To our knowledge, this study is the 
first of its kind to examine whether innovation-values fit moderates the effect of 
implementation climate on implementation effectiveness (Klein & Sorra, 1996). Our 
study extends the literature surrounding the theory of innovation implementation. For 
example, our results are consistent with prior empirical investigations that 
implementation climate and innovation-values fit independently impact implementation 
effectiveness (Weiner et al., 2009) (Helfrich et al., 2007) (Holahan et al., 2004). In this 
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examination of the theory, however, we provided quantitative evidence as to the utility of 
the theory in a health and human services setting, where innovation implementation 
impacts clinical care. It is important to provide empirical evidence for the use of the 
theory in health services research as healthcare professionals have more professional 
autonomy and therefore differ from employees in a manufacturing or information 
systems company.   
Specific Findings  
Our first hypothesis was that implementation climate would have a direct effect 
on implementation effectiveness, or enrollment of patients in cancer clinical trials. This 
hypothesis was supported. Our results highlight the importance of a strong perceived 
implementation climate on physician enrollment of patients in clinical trials and 
physician participation in volunteer research more generally. Physicians who felt their 
organization was supportive, provided rewards, and instituted expectations enrolled 
more patients in clinical trials than physicians who did not view their organization as 
having a strong implementation climate. This was likely the case as physicians felt that 
they had the skills necessary to enroll patients, the support they needed, and incentives 
were in place to encourage enrollment. CCOPs and other voluntary research programs 
may want to focus their efforts on creating an environment that physicians perceive as 
supporting implementation. For example, there is no “magic” number regarding the 
number of support staff needed to help screen or enroll patients, rather physicians need 
to feel that they are supported and perceive that they get what they need to identify and 
enroll patients in clinical trials.  
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Second, we hypothesized that innovation-values fit modifies the effect of 
implementation climate on implementation effectiveness among CCOP physicians. This 
hypothesis was partially supported. Including the moderator improved model fit and 
explained 3% of the overall variation in implementation effectiveness, although it was 
just barely insignificant. Explaining 3% of the overall variance, however, is noteworthy. 
Moderator effects are notoriously difficult to detect that even those explaining as little as 
1% of the variance can be considered important (Evans, 1985) (Champoux & Peters, 
1987). In a review of the social science literature, interactions typically account for about 
1-3% of the variance in outcome (Chaplin, 1991) (Hofmann et al., 2003). Perhaps 
innovation-values fit as a moderator was just slightly insignificant in our study because 
both implementation climate perceptions and innovation-values fit were strong across all 
physicians as indicated by high mean values for all of the innovation-values fit and 
climate perceptions questions (Table 6). Our results indicate that physicians in general 
viewed CCOP participation as aligning with their values and their CCOP as providing 
the necessary resources to enroll patients.  Therefore, given the already strong 
implementation climate and sense innovation-values fit, the moderating effect of 
innovation-values fit itself was small. This is likely because CCOP is a voluntary 
program and our sample was composed of physicians who want to participate. This 
finding is important for programs to consider, as ensuring that clinical research aligns 
with physicians’ values is not enough to overcome negative perceptions of 
implementation climate. 
In addition, innovation-values fit was a significant predictor of implementation 
effectiveness. Physicians, who wanted to participate in CCOP, perceived that 
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participating in CCOP was important, and valued participating enrolled more patients in 
trials than physicians who did not perceive that participating in CCOP aligned with their 
values. Therefore, our study also demonstrates that it is important for physician-based 
research networks to recruit physicians who value participating in clinical research. 
Overall, our results indicated that both implementation climate and innovation-values fit 
independently determined active physician participation in clinical research.  
Lastly, the hypothesis that physician characteristics (e.g., age, specialty, and 
practice location) would directly impact implementation effectiveness was also partially 
supported. Only status as the CCOP PI significantly influenced the enrollment of 
patients. PIs are more likely than non-PIs to be committed to the CCOP and feel 
obligated to set a “good example” for their colleagues. PIs may also be more familiar 
with available trial protocols and receive greater assistance from support staff to 
consent and enroll patients. Surprisingly, practice location, foreign medical training, 
medical specialty, age, and tenure did not impact enrollment.  Practicing at a hospital or 
as a solo physician (compared to a group practice) may not have had a significant effect 
because many CCOP physicians travel between different offices, which may make their 
primary location less relevant. We suspect that foreign medical training did not impact 
enrollment because we could not determine how long physicians had been practicing in 
the U.S., which is likely a more relevant predictor of enrollment than training location. In 
addition, medical specialty may not be as influential on enrollment as there are an 
abundance of types of cancer clinical trials, including protocols for surgery and 
radiological interventions. Therefore, all specialties are comfortable and willing to enroll 
patients in cancer trials.  Perhaps age and years in practice (tenure) were also not 
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significant as all physicians receive trainings now in clinical research, either through 
medical school or continuing medical education.  
Limitations  
There are several limitations of our study. First, we were limited in the data that 
was available to test the model of innovation implementation. We were most interested 
in the role of implementation climate and innovation-values fit on implementation 
effectiveness, but we did not have relevant data to allow us to examine some of the 
other model constructs (e.g., innovation effectiveness, strategic accuracy of innovation 
adoption).  Given we were only able to explain 38% of the total variation in enrollment, 
there are clearly other relevant factors of implementation effectiveness that we were not 
able to capture in this analysis. In addition, given that we only included physicians who 
participate in CCOP, our findings may not be relevant for physicians practicing in other 
settings. CCOP physicians volunteer to participate in CCOP. Therefore, our findings are 
most relevant to encourage active participation in CCOP. Other organizations, however, 
that want to increase physician participation in volunteer research should consider 
fostering perceptions of a strong implementation climate as well as consider recruiting 
physicians whose values align with program’s goals. 
Future Research   
Although innovation-values fit was not a statistically significant moderator in this 
context, future work should explore this proposed relationship further. Innovation-values 
fit may be a significant moderator in contexts where innovation implementation is 
mandatory and there is more variation in the perceptions regarding innovation-values fit 
and implementation climate. For example, if employees are forced to adopt an 
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innovation, those that feel that the innovation aligns with their values will be more likely 
to adopt and use the innovation, regardless of climate. A strong sense of innovation-
values fit will also likely strengthen their perceptions of their organization’s 
implementation climate as they are enthusiastic about the innovation and are committed 
to using it. If innovation-values fit is weak and users are forced to implement an 
innovation, they are likely unenthusiastic and unwilling to implement regardless of the 
organization offering incentives to adopt.  
We were interested in explaining variation in enrollment among individual 
physicians, which led to our testing the model at the individual level. Future studies, 
however, should test this relationship at the organizational level to examine whether 
innovation-values fit moderates the effect of implementation climate on implementation 
effectiveness. For example, although our intraclass correlations are modest, due to low 
between group variance, our relatively high interrater agreement statistics indicate that 
we likely have enough within group agreement to aggregate our variables to the CCOP 
level (Hofmann & Stetzer, 1996).  We could explore this further using a cross-level 
moderation test in multilevel modeling.  
Conclusion  
 
Through this analysis we were able to extend both the literature regarding the 
theory of innovation implementation and individual CCOP physician implementation 
effectiveness variation. In this study, we were able to add to the theoretical literature by 
not only empirically examining the theory of innovation implementation in a health and 
human services setting, but also by testing if innovation-values fit moderates the effect 
of implementation climate on implementation effectiveness, as suggested by Klein and 
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Sorra (1996). We also offered suggestions for CCOPs and other volunteer provider-
based research networks about how to engage physicians in clinical research through 
fostering a strong implementation climate as well as ensuring physicians’ values align 
with programmatic goals.   
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CCOP$Survey$Respondents$n=481
Mean%or%Proportion%of%Sample% Range
2011%Patient%%Enrollment% 4.7*%
(8.1)
%0,%62
Gender
!!!Male 74%
!!!Female! 26%
Race
!!!White 75%
!!!Asian 15%
!!!African2American! 1%
!!Other 9%
Expectations:$Enroll%Patients 3.4
(1.5)
1,5
Expectations:$Help%CCOP 4.2
(1.1)
1,5
Support:$Identify%Patients% 3.8
(1.3)
1,5
Support:$Enroll%Patients% 4.1
(1.2)
1,5
Rewards:$Recognition% 3.2
(1.3)
1,5
Rewards:$Appreciation% 3.3
(1.3)
1,5
Want$to$Offer$Trials 4.8
(0.5)
1,5
Participation$in$Important 4.7
(0.6)
1,5
Trials$Explore$Important$Issues 4.6
(0.7)
2,5
Value$Participating 4.7
(0.6)
1,5
Control'Variables:'Individual'Physician''Characteristics'
Age 52.6
(9.8)
34,82
Practice$Type
!!!Group!Practice 78%
%%%Hospital2Based 12%
!!!Solo!Practice 4%
!!Other/None!Listed 6%
Training$Location$
!!!U.S!Trained 80%
!!!Non!U.S!Trained 20%
Tenure$(Yrs.$In$Practice) 25.7 %8,%57
Medical$Specialty$
!!!Hematology!Oncology 40%
!!!Radiation!Oncology 21%
!!!Other!Specialty 18%
!!!Medical!Oncology 11%*
!!!Surgery! 10%*
Principal$Investigator$ 9%
*Indicates%significant%difference%between%survey%respondents%and%nonPsurvey%respondents%
Other!race%includes%American%Indian,%Native%Hawaiian/Pacific%Islander,%More%than%one%race,%or%unknown
Hematology!oncology%includes%blood%banking,%hematology%oncology,%hematology
Radiation!Oncology%includes%diagnostic%radiology,%nuclear%medicine,%radiation%oncology,%radiology,%vascular%and%interventional%radiology
Other!specialist%includes%general%practice,%gynecological%oncology,%%pediatrics,%pediatric%hematology,%cardiovascular%disease%etc.%
Surgery%includes%colon%and%rectal%surgery,%critical%care%sugary,%general%surgery,%neurological%surgery,%surgical%oncology,%urological%surgery%etc.%
Descriptive'Variables
Outcome'
Table$6:$Descriptive$Statistics$Aim$2
Standard%deviations%in%parentheses%
Predictor'Variable:'Perceived'Implementation'Climate'
Moderator:'Innovation<Values'Fit'
able 6: Descriptive Statistics, Aim 2 
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Factor'
Unstandardized'
Estimates' Standard'Error'
Standardized'
Estimates' Standard'Error'
Implementation+Climate 3.12* 1.15 0.29* 0.10
Innovation.Values+Fit+ 4.42* 1.26 0.18* 0.05
Latent+Variable+Interaction+ 5.19 2.73 0.16 0.09
Age >0.13 0.10 >0.16 0.12
Hospital,Based^0 >1.47 0.89 >0.06 0.04
Solo0Practice^ 0.86 1.32 0.02 0.04
Non0U.S.0Trained >0.30 0.97 >0.01 0.05
PI 8.95* 2.14 0.31* 0.07
Tenure 0.09 0.09 0.12 0.12
Hematologist0Oncology^^ >1.44 1.40 >0.09 >0.08
Radiation0Oncology^^ >2.01 1.57 >0.10 0.08
Surgery^^0 >2.13 1.78 >0.08 0.07
Other0Specialty^^ >2.68 1.46 >0.13 0.07
Latent&Variable:&Implementation&Climate&
Expectations:0Enroll0Patients 0.56* 0.14 0.10* 0.03
Expectations:0Help0CCOP 0.75* 0.16 0.10* 0.02
Support:0Identify0Patients 1.04* 0.12 0.16* 0.02
Support:0Enroll00Patients 0.94* 0.12 0.14* 0.02
Rewards:0Recognition 1.00 0.00 0.16* 0.01
Rewards:0Appreciation 0.89* 0.06 0.14* 0.01
Latent&Variable:&Innovation3Values&Fit
Want0to0Offer0Trials 1.00 0.00 0.06* 0.01
Participation0is0Important 1.83* 0.14 0.15* 0.01
Trials0Explore0Important0Issues 1.02* 0.14 0.08* 0.01
Value0Participating 1.63* 0.13 0.12* 0.01
*Statistically0Significant0at0p<0.05
^Compared0to0Group0Practice
^^Compared0to0General0Non,Specialized0Oncology
Table+7:++SEM+Results+Aim+2
Outcome:&Enrollment&in&NCI3Sponsored&Cancer&Clinical&Trials&in&2011
Model'Fit'Statistics:'CFI=0.967;'TLI='0.961;'RMSEA=0.032;'SRMR=0.051
Table 7: SEM Results, Aim 2 
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Figure 4: Determinants and Consequences of Implementation Effectiveness, as 
Illustrated in Klein & Sorra, 1996 
Figure 5: Determinants, Consequences, and Modifiers of Implementation Effectiveness, 
as Articulated in Klein & Sorra, 1996; Weiner, 2011 
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Innova&on'Values-Fit-
•  Want%to%oﬀer%clinical%trials%
in%prac/ce%%
•  Par/cipa/ng%in%clinical%trials%
is%important%%
•  Trials%explore%issues%that%are%
important%in%prac/ce%
•  Value%par/cipa/ng%in%trials%%
Implementa&on-Eﬀec&veness-
-Individual%physician%enrollment%
of%pa/ents%in%cancer%clinical%
trials%
Figure%6:%Determinants%and%Modiﬁers%of%Implementa/on%Eﬀec/veness%Model,%as%Tested%%%
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•  Expecta/ons%for%enrollment%%
•  Expecta/ons%to%help%CCOP%
meet%its%goals%
•  Support%needed%to%iden/fy%
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Figure 6: Determinants and Modifiers of Implementation Effectiveness Model, as Tested 
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Figure 7: Standardized SEM Results, Aim 2 
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CHAPTER 6: DETERMINING THE PREDICTORS OF INNOVATION 
IMPLEMENTATION IN HEALTHCARE: A QUANTITATIVE ANALYSIS OF 
IMPLEMENTATION EFFECTIVENESS 
 
Overview  
 
With healthcare reform, healthcare organizations will need to implement 
innovations. Unfortunately, the failure rate for implementing innovations is high, with 
upwards of 50% of failures due in part to the high uncertainty, risk, and clinical 
discretion required to practice medicine. Klein and Sorra’s (1996) innovation 
implementation framework offers a promising approach to examine the organizational 
factors that determine effective implementation. To date, the utility of this framework in a 
healthcare setting has been limited to qualitative studies and/or group level analyses. 
To enhance this models’ usefulness in explaining innovation implementation among 
individuals, further research is needed to examine whether key relationships can be 
supported quantitatively. Therefore, the goal of this study was to examine this 
framework among individual participants in the National Cancer Institute’s Community 
Clinical Oncology Program using structural equation modeling. Our results have 
implications for both the implementation of innovations in clinical practice and for 
innovation implementation theory.  
Background  
 
Healthcare organizations continuously need to implement complex innovations. This is 
truer now than ever, as the Patient Protection and Affordable Care Act (ACA) introduces 
innovative payment and delivery arrangements such as Accountable Care 
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Organizations, bundled payments, patient-centered medical homes, and value-based 
purchasing (ACA, 2010). Unfortunately the failure rates for implementing complex 
innovations are high. Estimates range from 30% to 90% depending on the scope of the 
organizational change involved, the definition of failure, and the criteria to judge it. 
(Alexander & Hearld, 2011) (Alexander et al., 2006) (Berlowitz et al.,2003). Innovations 
in healthcare often fail due in part to poor implementation (Alexander & Hearld, 2011) 
(Nembhard, et al., 2009), which can result from the high uncertainty, risk, and clinical 
discretion required to practice medicine, stronger professional identification among 
physicians compared to organizational identification, and perceived conflict of goals 
between leaders and workforce (Nembhard et al., 2009). Additional reasons for failure 
include misaligned incentives for adoption, unsustained leadership, lack of support 
and/or training, competing priorities, and resistance to change (Alexander & Hearld, 
2011) (Shortel et al., 1998) (Rivera, 1999). Implementation failure may not only result in 
the loss of time and money for the organization, but can also impact the quality of care 
patients receive.  
Theories of innovation implementation offer a promising approach to examine 
organizational factors that influence effective implementation (Klein & Sorra, 1996). 
Although the framework was developed in manufacturing contexts, it has been 
increasingly applied to innovation implementation in healthcare (Klein & Sorra, 1996) 
(Weiner et al., 2011) (Helfrich et al., 2007) (Naveh & Marcus, 2004). To date, most of 
the evidence supporting its use in healthcare is qualitative in nature (Weiner et al., 
2011) (Weiner et al., 2012) (Teal et al., 2012) (Weiner et al., 2009) (Helfrich et al., 
2007). Although important, qualitative studies tend to use small sample sizes, have 
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limited external generalizability, and present challenges in standardizing the 
measurement of key constructs. Currently, the majority of quantitative studies testing 
this framework have examined the effectiveness of technology implementation among 
company employees in information systems and computing organizations (Dong et al., 
2008) (Holahan et al., 2004) (Klein et al., 2001) (Osei-Bryson et al., 2008) (Sawang & 
Unsworth, 2011) (Leiva et al., 2011) (Mollaoglu-Korkmaz et al., 2013). These settings 
are difficult to compare to healthcare because: (1) physicians experience greater 
professional autonomy, and (2) the process of implementing computing technology 
offers greater standardization than delivering clinical care or implementing innovative 
care delivery models.  
It is important to quantitatively examine Klein and Sorra’s framework as it will 
allow for a more precise examination of proposed hypotheses as well as allow 
researchers to compare results across settings, samples, and innovations. A 
quantitative analysis also allows researchers to control for other explanatory variables 
that may predict implementation effectiveness, which is difficult to do with qualitative 
research. Therefore, we quantitatively tested Klein and Sorra’s innovation 
implementation framework in the National Cancer Institute (NCI)’s Community Clinical 
Oncology Program (CCOP), a provider-based research network focused on the 
enrollment of patients in cancer clinical trials (Minasian et al., 2010). Using both survey 
and archival data, we examined the hypothesized relationship among core constructs of 
the model using structural equation modeling (SEM). Specifically we sough to 
investigate the role of implementation climate and organizational implementation 
policies and practices (IPP) in determining effectiveness of innovation implementation. 
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Our research not only extends the literature surrounding innovation implementation 
theory, but it also has important practice implications for implementing innovations in 
complex, rapidly changing healthcare organizations.  
New Contribution  
This study is one of first to quantitatively test Klein and Sorra’s (1996) innovation 
implementation framework in a healthcare context. As such, it will provide important 
evidence regarding the utility of this framework in explaining innovation implementation 
in healthcare. In addition, the framework tested in this paper focuses on implementation 
among individual physicians, rather than at the organizational or group level which is 
common when testing innovation implementation models (Dong et al., 2008) (Holahan 
et al., 2004) (Klein et al., 2001) (Sawang & Unsworth, 2011) (Muilenburg et al., 2013). 
This is a critical advancement because many innovations in healthcare are implemented 
voluntarily by individual physicians. Therefore, it is important to understand the 
organizational determinants of innovation implementation among physicians. Overall, 
study findings will allow researchers and managers to have a better understanding 
regarding the role of implementation climate and organizational policies and practices in 
determining the effectiveness of an innovation in clinical practice. 
Methods  
 
Conceptual Framework   
 
The conceptual model for this study is based on Klein and colleagues’ framework 
of innovation implementation which specifics the antecedents of complex innovation 
implementation (Klein & Sorra, 1996) (Klein et al., 2001). The framework postulates that 
implementation effectiveness, or the consistency and quality of innovation use, results 
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from both organizational implementation policies and practices (IPP) and individual 
climate perceptions (Figure 8). IPP are the formal strategies organizations use to put 
the innovation into use, while implementation climate is the extent to which 
organizational members perceive that an innovation is expected, supported, and 
rewarded by their organization (Klein & Sorra, 1996) (Helfrich et al., 2007) (Klein et al., 
2001). Specifically, the authors suggest that IPP are the antecedents of climate, while 
individuals’ interpretive perceptions of climate ascribe meaning to the policies and 
practices (James & Jones, 1974). Therefore, how physicians view their organization in 
terms of encouraging innovation implementation is determined by IPP. In addition, these 
perceptions predict the number of patients each physician enrolls in a cancer clinical 
trial (i.e., implementation effectiveness).   
Hypothesis 1: IPP will have a positive indirect effect on implementation 
effectiveness operating through implementation climate perceptions. 
 
A strong implementation climate ensures organizational members, or in this case 
physicians, have the skill and support needed to implement the innovation, incentives to 
participate are in place, and obstacles to implement are limited. In this setting, strong 
perceptions of implementation climate should directly lead to stronger implementation 
effectiveness (higher patient enrollment among physicians). This is because 
perceptions that a CCOP institutes accrual expectations, provides support for the 
enrollment of patients, as well as recognizes enrollment efforts should encourage 
physicians to enroll more patients in cancer clinical trials. 
Hypothesis 2: Perceptions of implementation climate will have a direct positive 
effect on implementation effectiveness.  
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Given our interest in examining innovations that do not require interdependent use by 
multiple individuals, we needed to modify the Klein & Sorra model to ensure that the 
constructs were relevant at the individual level (Klein & Kozlowski, 2000). For example, 
we were interested in examining individual physician participation in CCOP because of 
the significant variation that occurs in enrolling patients in cancer clinical trials. Thus, we 
added control variables such as physician characteristics (e.g., physician age, years of 
experience, specialty, practice type, training location, and CCOP Principal Investigator 
(PI) status), as we believed these characteristics would both influence physicians’ 
perceptions of climate and their ability to enroll patients in cancer clinical trials. For 
example, experience and age may influence perceptions, as older and more 
experienced physicians may perceive they have access to more resources, as well as 
enrollment, as more experienced physicians or CCOP PIs may be more familiar with 
clinical trials and enroll more patients.  
Hypothesis 3: Physician characteristics will have both direct and indirect effects, 
operating through perceptions of implementation climate on implementation 
effectiveness.   
 
Lastly, we included organizational control factors, such as structure, years in existence, 
and size in our model. For example, we believed larger organizations that are part of a 
cancer center or research institute may have more resources to encourage innovation 
implementation compared to smaller, non-profit independent organizations. In addition, 
we believed that CCOPs that had been in existence longer would likely have more 
resources and thus provide more trainings and offer greater incentives for physicians to 
enroll patients.  
Hypothesis 4: Organizational factors will have an indirect effect on 
implementation effectiveness operating through IPP and perceptions of 
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implementation climate.  
 
Study Setting  
 
The study was conducted in NCI’s CCOP network. In brief, the goals of the 
CCOP network are to advance the evidence-base by conducting research in clinical 
settings where most people receive their care, and translate results into better care 
(Kaluzny et al., 1994) (Minasian et al., 2010). The CCOP network is a joint venture 
between NCI’s Division of Cancer Prevention, who provides overall direction and 
funding for community hospitals and practices to participate in clinical trials, selected 
cancer centers and clinical cooperative groups (CCOP research bases), who design the 
trials, and community-based physicians and hospitals (CCOP organizations) care, who 
assist with patient enrollment, data collection, and dissemination of study findings 
(Kaluzny et al., 1994) (Minasian et al., 2010). CCOP organizations are generally 
composed of a physician CCOP PI who provides local program leadership, a team of 
support staff, as well as affiliated physicians who enroll patients in NCI-sponsored 
cancer clinical trials (Weiner et al., 2011) (Teal et al., 2012). CCOP-affiliated physicians 
include specialized oncologists (e.g., hematological, surgical and radiation oncologists), 
general medical oncologists, and other medical specialists (e.g., urologists, 
gynecologists, and gastroenterologists). 
In 2011, when the study was conducted, the CCOP network consisted of 47 
CCOP organizations across 28 states, the District of Columbia, and Puerto Rico and 
included 400 hospitals and 3,520 community physicians. CCOP organizations consisted 
on average of 10 community hospitals or physician practices and 48 physicians.  
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Data Sources and Data Collection Procedures  
 
The data for this cross-sectional study were obtained from four sources. First, the 
2011 CCOP Annual Progress Reports, submitted in March 2012, provided data on 
physicians’ enrollment activities during the period from June 1, 2011 to February 29, 
2012. The reports were mainly used in determining the outcome, physician enrollment 
of patients in trials. Each March, every CCOP submits a progress report to NCI detailing 
the previous nine-month’s research and enrollment activities. The report includes 
standardized questions regarding the allocation of CCOP resources, staffing 
assignments, total cancer patient volume, the number of open cancer clinical trials, the 
total number of patients each CCOP enrolls, as well as the total number of patients 
each individual CCOP-affiliated physician enrolls.  
This study also used the 2011 CCOP Physician Survey and the 2011 CCOP 
Administrator Survey, which were both designed and administered as part of a larger 
NCI-funded-study (5R01CA124402). The goal of the physician survey was to learn 
more about physician participation in the CCOP program, while the administrator survey 
collected information regarding CCOP policies and procedures. The physician survey 
included specific questions regarding their perceptions surrounding expectations for 
enrollment, research support provided by the CCOP, ability to provide input, how well 
they are kept informed of CCOP activities, recognition received from the CCOP, as well 
as attitudes regarding the importance of cancer clinical trials. The survey specifically 
supplied data on CCOP physicians’ perceptions of implementation climate.   
The sampling frame for the physician survey included all CCOP-affiliated 
physicians eligible to accrue patients to clinical trials.  Between October 2011 and 
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January 2012, we surveyed 817 physicians using a random sample stratified across all 
47 CCOPs. One week after sending potential respondents, a postcard announcing the 
survey and highlighting its importance to NCI, physicians were sent a cover letter 
explaining the goals of the survey, the survey itself, a self-addressed and stamped 
return envelope, and a $50 Visa gift card as an incentive to complete the survey. 
Physicians were also able to complete the survey online via a unique access code 
provided in the mailings. A thank-you or reminder postcard was then sent the following 
week. Approximately three weeks after the first mailing, non-respondents received a 
second copy of the survey, cover letter, and return envelope. Lastly, we contacted 
CCOP PIs and administrators to email the non-responding physicians affiliated with 
their CCOP requesting them to complete the survey. On average, 17 physicians were 
surveyed per CCOP, and 10 physicians responded per CCOP organization. 
The administrator survey included questions relating to the CCOP’s 
organizational structure and size, performance management, education and trainings, 
protocol selection practices, research support, and staffing. The survey specifically 
supplied data on CCOP’s IPP and the organizational control factors. The survey was 
completed by 100% of CCOP administrators. The vast majority of administrators 
completed the survey at the 2011 annual CCOP meeting, held each September at NCI. 
We followed up via email with administrators that did not complete the survey in person. 
Any remaining surveys were completed between October 2011 and January 2012.  
Lastly, the 2012 American Medical Association (AMA) Physician Masterfile 
provided data for the physician characteristics. Established by the AMA in 1906, the 
Physician Masterfile includes current and historical data for more than 1.4 million 
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physicians, residents, and medical students in the U.S, including data on demographics, 
specialty, experience, medical school training, and residency.  
Measures  
 
The outcome of this study was implementation effectiveness, which was 
operationally defined as the number of patients that each physician enrolled in cancer 
clinical trials in 2011. The NCI uses this objective, outcome-focused measure as the 
primary means of determining CCOP physician performance, as do several other 
studies (Jacobs et al., 2014).  
Key Constructs  
The organizational implementation policies and practices (IPP) construct 
included five measures from the CCOP Administrator Survey. To measure expectations 
for enrollment, administrators were asked whether their CCOP expects physicians to 
enroll a minimum number of patients in clinical trials. Three measures addressed CCOP 
support for enrollment activities: 1) proportion of physicians for whom CCOP staff 
members routinely screen patient charts for potentially eligible patients; 2) proportion of 
physicians for whom CCOP staff members routinely assist with enrollment; and 3) 
whether or not CCOP sponsor any events where physicians could learn about the latest 
developments in cancer research, treatment, prevention, or control. Lastly, to assess 
rewards, administrators were asked whether the CCOP provides some form of 
recognition to physicians with high levels of accrual to NCI-sponsored trials.  
The perceptions of implementation climate construct included six measures from 
the CCOP Physician Survey that were consistent with prior studies examining 
perceptions of implementation climate (Klein & Sorra, 1996) (Weiner et al., 2011) (Teal 
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et al., 2012). Two measures addressed whether physicians were: 1) expected to enroll 
a certain number of patients in trials and 2) expected to help the CCOP meet its patient 
enrollment goals. Two measures addressed whether physicians get the support they 
needed to: 1) identify potentially eligible patients and 2) enroll patients in trials. Lastly, 
two measures addressed whether physicians received: 1) recognition and 2) 
appreciation when they enroll patients in trials. For all measures, physicians could 
respond disagree, somewhat disagree, neither agree nor disagree, somewhat agree, or 
agree 
Control Variables  
We also included both physician characteristics and CCOP organizational factors 
as controls. Physician characteristics included age, whether or not they trained in the 
United States, self-designated medical specialty (e.g., hematologist oncologist, surgeon, 
radiological oncologist, general oncologist, non-oncologist specialist), and whether or 
not the physician was the CCOP PI. We also included the practice arrangement (i.e., 
hospital-, group-, or solo- based) and how long the physician had been in clinical 
practice. The organizational factors included CCOP organizational structure (e.g., 
hospital cancer center or cancer service line, research institute, department or center, 
separate non-profit organization), size (i.e., number of locations patients can enroll in a 
clinical trial), and how long the CCOP has been in existence.  
Data Analysis  
 
SEM with maximum likelihood estimation was used to simultaneously test 
whether perceptions of implementation climate mediates the relationship between IPP 
and implementation effectiveness. SEM is composed of multivariate regression models 
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and can be used to estimate proposed causal relationships (Norman & Streiner, 2003) 
(Hox & Bechger, 2007) (Schreiber et al., 2006). We used confirmatory SEM to test the 
hypothesized pathways among implementation factors represented in Figure 9 by 
comparing how well this proposed structure fits the observed data. We selected SEM 
because it allowed us to test for constructs that are not directly assessed, but are 
instead composed of observed indicators representing the constructs of interest (e.g., 
IPP, perceptions of implementation climate). 
The goal of SEM is to achieve a well-fitting model based on theory (Norman & 
Streiner, 2003) (Hox & Bechger, 2007) (Schreiber et al., 2006).  Therefore, a priori, we 
believed that the two measures that composed each of the three components of 
perceptions of implementation climate (i.e., support, reward, expectations) would co-
vary higher than with measures representing the other components. For example, the 
two measures that compose expectations, physicians are expected to enroll a certain 
number of patients and are expected to help the CCOP meet its goals, likely share 
common variation that is not explained by any of the proposed relationships in the 
model. Therefore we decided a priori to add three covariances, one between each of 
the two measures that address expectations, support, and rewards. We also elected to 
use clustered robust standard errors to account for clustering of physicians within 47 
CCOPs. 
We then evaluated model fit using the Comparative Fit Index (CFI) and the 
Tucker-Lewis Index (TLI). CFI and TLI values range from 0 to 1, with values ≥ 0.90 
representing adequate fit (Norman & Streiner, 2003) (Schreiber et al., 2006). We also 
examined the root mean square error of approximation (RMSEA) and the associated 
 92 
 
confidence interval and p-value. RMSEA values < 0.06 and an upper bound of the 
confidence interval < 0.1 are considered acceptable. Next, we examined the 
standardized root mean squared residuals (SRMR), with values < 0.08 considered 
acceptable fit (Schreiber et al., 2006).  
Based on these fit statistics for the original model, we elected to re-specify our 
original model to improve its fit. SEM is an iterative process in which model fit is 
improved by using theory and modifications indices either to add additional pathways 
between variables or to allow items to co-vary (Norman & Streiner, 2003) (Hox & 
Bechger, 2007) (Schreiber et al., 2006). Modification indices are the minimum that the 
chi-square statistic is expected to decrease if the corresponding parameter is no longer 
assumed to be fixed at zero (Norman & Streiner, 2003). Therefore, we added four 
additional co-variances to the original model. With the addition of each error-term co-
variance, we tested whether model fit improved by examining the baseline model 
against the new model using the Lagrange multiplier test and fit statistics.  
Once we achieved a well fitting SEM model, we evaluated our model by testing 
the significance of all standardized estimates. To examine standardized direct and 
indirect effects, we used bootstrapping with 95% confidence intervals on 1,000 
bootstrap estimates.  We elected to use bootstrapping to correct for non-normality, 
given the power of the joint test of two pathways in mediation analysis is larger than the 
power of the test of their product when using the usual z test and the associated 
confidence intervals for the product (MacKinnon, 2008).  This appears to be due to the 
non-normality of the product. Specifically, indirect effects are the product of the two 
regression coefficients. For example, if X predicts Y and Y predicts Z, then the indirect 
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effect of X on Z equals the product of the two regression coefficients (X on Y and Y on 
Z). Lastly, to ensure the validity of our SEM results, we checked our results using 
negative binomial regression analysis with clustered robust standard errors. Analyses 
were performed using Mplus 7.  
RESULTS  
 
Descriptive Statistics  
 
The final sample for this study included 481 physicians with complete data on the 
2011 CCOP-Affiliated Physician Survey (Table 8).  The vast majority of the sample was 
male (74%), White non-Hispanic (75%), practiced in a group practice (78%), and trained 
in the U.S (80%). The mean age was approximately 53 years old and physicians on 
average had been in practice approximately 26 years. Over 70% were oncology-based 
specialists and 9% were the CCOP PI. Physicians on average enrolled close to five 
patients in a cancer clinical trial in 2011. In addition, physicians generally agreed that 
their CCOP encouraged implementation. The average response on all six questions 
relating to implementation climate was 3.6 on a scale of one to five. Physicians on 
average rated the two reward items the lowest (Item 1: 3.2; Item 2: 3.4) and the 
expectation and support items more favorably (Expectations item 1 & 2: 3.4 and 4.2; 
support items 1 & 2: 3.8 and 4.1). The only significant (p<0.05) differences between 
survey responders and non-responders were that responders enrolled more patients 
per year (4.7 versus 3.4), were more likely to be a surgeon (10% versus 5%), and were 
less likely to be a non-specialized general oncologist (11% versus 24%). 
For the CCOPs (n=47), the average number of years in existence was over 25 
(Table 9). The average size, as determined by the number of locations a patient could 
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enroll in a clinical trial, was 14 and the majority of CCOPs were a hospital cancer center 
or cancer service line (40%), although 30% were a separate non-profit organization and 
24% were a research institute, department, or center. The majority of CCOPs did not 
institute a minimum number of patients physicians should enroll per year (65%), did not 
offer trainings or events where physicians could learn about the latest developments in 
cancer research (58%), but did provide some form of recognition to physicians with high 
levels of accrual (62%).  In addition, about 50% of physicians within a CCOP had 
support staff members help screen patient charts for potentially eligible patients and 
assist with enrollment.  
SEM Measurement Analysis  
 
The fit statistics and modification indices for the fixed parameters of the original 
model suggested that we re-specify the model to improve fit (CFI = 0.846 TLI = 0.815; 
RMSEA = 0.068; SRMR = 0.052) (Figure 9). Therefore, we added four post-hoc 
modifications that were theoretically justified and improved model fit (Figure 10). For 
these modifications, we allowed the error terms of the following measures to co-vary 
higher than with other variables. For example, the percentage of doctors supported in 
screening and enrolling patients, likely share common variation that is not explained by 
any of the proposed relationships in the model.  
1) The percentage of doctors supported in screening and enrolling patients: The 
same support staff generally preform both functions within a CCOP.  
2) Trainings offered with the percentage doctors who are supported in screening 
patients: The number of trainings offered relates to the number of support 
staff available. 
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3) Trainings offered with the percentage doctors who are supported in enrolling 
patients: The number of trainings offered relates to the number of support 
staff available. 
4) Rewards with expectations for enrollment: CCOPs that provide incentives 
may also be more likely to have expectations for enrollment.  
With the addition of each error-term co-variance, we tested whether model fit improved 
by examining the baseline model against the new model using the Lagrange multiplier 
test and fit statistics. Figure 10 provides a graphic version of the final standardized 
bootstrapped SEM results. Standardized bootstrapped total, direct, and indirect effects 
are provided in Table 10.  Overall, we achieved a final well-fitting model (CFI = 0.933; 
TLI = 0.918; RMSEA = 0.045; SRMR = 0.048) and explained approximately 24% of the 
total variation in implementation effectiveness.  
Regarding the IPP construct, the majority of the construct was determined by 
expectations for enrollment (β=0.82), although all five measures were statistically 
significant (p<0.05). In addition, regarding the perceived implementation climate 
construct, all six measures were statistically significant determinants of the construct 
(p<0.05). The largest determinants were perceptions regarding the organization’s 
recognition and appreciation of enrollment activities (β= 0.62; β=0.56) as well as 
perceptions regarding support provided to screen and enroll eligible patients (β= 0.61; 
β=0.59) (Figure 10). 
SEM Structural Analysis  
Hypothesis one was supported, as physicians’ perceptions of implementation 
climate mediated the relationship between IPP and enrollment. This means there was a 
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significant indirect effect between IPP and enrollment operating through perceptions of 
implementation climate (indirect effect = 0.069; p=0.01) (Table 10). Although our final 
model suggested that implementation climate fully mediated the relationship between 
IPP and implementation effectiveness, we could also envision scenarios where IPP 
directly influenced implementation effectiveness. For example, in addition to helping to 
shape perceptions of implementation climate, the number of staff available at each 
CCOP to screen and enroll patients might also directly determine the number of patients 
a physician was able to enroll in a clinical trial. Therefore, we also tested an alterative 
model (Figure 11) where there was a direct pathway between IPP and implementation 
effectiveness. This alternative model fit the data well (CFI = 0.934; TLI = 0.918; RMSEA 
= 0.045; SRMR = 0.047). The results demonstrated that there also was a significant 
direct effect of IPP on implementation effectiveness (direct effect = 0.10; p=0.04). 
Therefore, perceptions of implementation climate only partially mediated the relationship 
between IPP and implementation effectiveness, as there was also a direct relationship 
between the two constructs.  
Hypothesis two was also supported as perceptions of implementation climate 
had a statistically significant direct effect on implementation effectiveness (direct effect = 
0.285; p<0.00). Hypothesis three was partially supported given CCOP PI status, age, 
radiological oncologists, and non-oncologist specialists significantly influenced 
enrollment while training location, tenure, practice location, and physicians who are 
surgeons, and hematologists (compared to non-specialized oncologists) did not directly 
influence implementation effectiveness. There was no evidence, however, that any of 
the physician characteristics significantly influenced implementation effectiveness 
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through their effect on perceptions of implementation climate. Lastly, hypothesis four 
was also partially supported as organizational size and structure indirectly influenced 
implementation effectiveness through IPP and implementation climate. However, 
organizational maturity did not significantly influence implementation effectiveness 
through its effect on IPP and perceptions of implementation climate. The robustness 
check of our SEM results using negative binomial regression analysis with clustered 
robust standard errors confirmed our main findings.  
DISCUSSION  
 
Overall Significance  
Overall, our results quantitatively confirmed the main relationship postulated by 
Klein and Sorra (1996) between IPP, implementation climate, and implementation 
effectiveness among individual physicians. It is often difficult to test this theory 
quantitatively given the large sample of participants and organizations required. 
Although the model has been discussed within healthcare organizations before, the 
studies have been predominately qualitative in nature. For example, Helfrich and 
colleagues (2007) demonstrated the relationship between IPP, implementation climate, 
and effectiveness using comparative case studies of four cancer clinical research 
networks implementing new programs in cancer prevention and control research. 
Similar results have also been confirmed in other settings. Sawang and Unsworth 
(2011) confirmed a similar model where implementation climate mediated the role of 
IPP and implementation effectiveness among small and medium businesses 
implementing different innovations in Australia. Both of these analyses, however, were 
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the model in healthcare to explain individual level innovations.  Although the model still 
must be tested at the organizational level in a healthcare setting, our results might have 
broad implications given that many innovations and evidence-based practices in 
healthcare are implemented by individual physicians on a voluntary basis. For example, 
the use of novel therapies often only require implementation by a single physician, not 
collective, coordinated implementation among multiple individuals in an organization. 
Our findings are also relevant to other implementation theories and frameworks. 
For example, our results can be used in conjunction with the Consolidated Framework 
For Implementation Research (CFIR). The CFIR offers guidance as to the possible 
predictors of implementation effectiveness, such as intervention characteristics, factors 
at the system and organizational levels, and characteristics of the individuals 
implementing the innovation (Damschroder et al., 2009). The CFIR does not, however, 
provide rationale as to why some domains may be more relevant than others and how 
they are related in certain circumstances. Therefore our results could be useful in 
selecting relevant constructs from the CFIR to examine implementation effectiveness of 
individually driven innovations in a healthcare setting. For example, as part of the inner 
setting or organizational level construct, the CFIR includes organizational 
characteristics, such as size and structure, which we found to be important 
determinants of organizational IPP. The inner setting also includes policies and 
practices related to implementation climate, such as organizational incentives and 
rewards, clearly communicated goals and feedback, available resources, and access to 
information through trainings, all of which were included in our model as IPP and/or in 
physicians’ perceptions of implementation climate. Lastly, the CFIR also includes 
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characteristics of the individual such as tenure, age, and experience. Our research 
indicates how these constructs not only relate to one another, but how they also impact 
implementation effectiveness.  
Specific Findings  
Our results demonstrated that implementation climate perceptions partially 
mediated the relationship between IPP and implementation effectiveness. Therefore, 
the policies and practices an organization has in place to encourage innovation 
implementation may be most effective if the intended users perceive these policies and 
practices as supportive.  Although there was a significant direct effect between IPP and 
implementation effectiveness, over a third of the total effect of IPP on implementation 
effectiveness resulted from the indirect effect of IPP on implementation effectiveness 
operating through perceptions of implementation climate. Therefore, even with 
supportive IPP in place, implementation could still fail if the intended users do not feel 
the effects of these IPP as encouraging implementation. In addition, the direct 
relationship between implementation climate and implementation effectiveness was 
almost three times greater than the relationship between IPP and implementation 
effectiveness. Thus, managers looking to increase implementation effectiveness of an 
innovation should focus on creating an environment that physicians perceive as 
encouraging implementation. For example, ensuring physicians feel that they are 
supported and perceive that they get what they need to effectively implement an 
innovation is more important than having a certain number of staff available or offering 
trainings in terms of encouraging implementation. 
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In addition, our results also confirmed that implementation climate should be 
composed of measures relating to expectations, support, and rewards, as suggested in 
Klein and Sorra’s (1996) theory of innovation implementation. Although, the authors 
suggest that implementation climate should be assessed at the group level as an 
aggregation of shared perceptions, our results demonstrate that implementation climate 
can also be measured at the individual level using the same theoretical construct. 
Managers should consider instituting specific organizational IPP aimed at increasing 
positive perceptions of climate in all three areas. For example, IPP should include 
specific expectations, support, and rewards for innovation use. 
Given the goal was to examine an innovation in healthcare implemented by 
individual physicians on a voluntary basis, we needed to adapt our model by including 
personal characteristics. We proposed that personal characteristics would have both 
direct effects on implementation effectiveness as well as indirect effects on 
implementation effectiveness operating through climate perceptions. However, we only 
found direct effects for some of the personal characteristics. Although we did find that 
status as the CCOP PI had a significant effect on climate perceptions, the indirect effect 
operating through climate perceptions on implementation effectiveness was not 
significant. Therefore intended users that are leaders or innovation champions may 
have more positive perceptions of climate compared to non-leaders. Overall, however, 
these results indicate that climate perceptions were mostly determined by IPP. Our 
findings suggest that there may be alternative ways in which personal characteristics 
relate to implementation effectiveness. For example, personal characteristics may have 
an influence on fit between the innovation and the organizational members’ values 
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(Klein & Sorra, 1996). Perhaps, more experienced physicians or physicians that have 
been at the organization longer perceive the innovation as more congruent with their 
individual values and therefore use the innovation in a more consistent and high-quality 
way. This should be tested in future studies.  In addition, it is possible that personal 
characteristics moderate the relationship between implementation climate and 
implementation effectiveness. For example, experience, or status as an innovation 
leader may strengthen the effect of perceptions of implementation climate on 
implementation effectiveness.  So, experience or status as a leader would intensify the 
relationship between implementation climate and implementation effectiveness. 
Therefore, future studies should examine other potential relationships between personal 
characteristics and implementation effectiveness.  
Our findings are also consistent with Klein and Sorra’s equifinality argument in 
that IPP have an indirect effect on implementation effectiveness through climate 
perceptions. Although implementation climate perceptions were the key determinant of 
implementation effectiveness, there are potentially multiple combinations of specific 
organizational IPP that may result in positive perceptions of implementation climate. 
More research is needed to demonstrate that different combinations of IPP can produce 
equivalent perceptions of implementation climate. Our study, however, presents one 
possible parsimonious model of climate and its role in determining implementation 
effectiveness.  
Limitations and Future Directions  
There are several limitations of our study. First, we only included physicians who 
participated in CCOP in our study. In addition, CCOP Physician Survey respondents 
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significantly enrolled more patients per year than survey non-respondents. Thus, we 
need to be careful in generalizing our results to all CCOP physicians as well other types 
of physicians.  Our findings might be most relevant to encourage active participation 
where innovation use is voluntary. We believe, however, that our findings are still 
relevant for administrators wanting to increase implementation of individual-focused 
innovations given our high response rate and overall there were few significant 
differences between survey respondents and non-respondents The study should be 
tested in other settings with a variety of innovations especially where participation or 
implementation is mandatory. Second, our study is cross-sectional and represents a 
single point in time. Future studies should consider examining implementation climate 
over the course of implementation to better understand how climate may vary over time 
or among different groups within a single organization. Third, our study only explained 
24% of the variance in enrollment. Therefore, future studies may want to explore 
additional factors, such as patient characteristics that may influence enrollment in 
cancer clinical trials. Lastly, although many innovations in healthcare are focused on the 
individual, it is important to also test this theory at the intended unit of analysis. 
Therefore future work should also consider investigating this framework at the 
organizational or practice level by aggregating implementation climate perceptions if 
possible.  
CONCLUSION  
Through this analysis we were able to extend the literature concerning the use of 
innovation implementation theories as well as provide practical suggestions for 
managers considering implementing an innovation. Our study not only provides 
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quantitative evidence that implementation climate mediates the relationship between 
IPP and implementation effectiveness, but it also demonstrates the utility of adapting an 
implementation framework to explain individually focused innovations. The majority of 
our hypotheses were supported, thus demonstrating the importance of physicians’ 
perceptions of implementation climate in determining implementation effectiveness. 
Therefore, managers looking to increase innovation implementation effectiveness 
should consider fostering a strong implementation climate through supportive IPP to 
encourage innovation use. 
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Table 8: Descriptive Statistics CCOP Physicians  
Mean%or%Proportion
%of%Sample% Standard%Deviation Range
2011%Patient%%Enrollment% 4.7*% 8.1 %0,%62
Gender
!!!Male 74%
!!!Female! 26%
Race
!!!White 75%
!!!Asian 15%
!!!African2American! 1%
!!Other 9%
Expectations:1Enroll%Patients 3.4 1.5 1,5
Expectations:1Help%CCOP 4.2 1.1 1,5
Support:1Identify%Patients% 3.8 1.3 1,5
Support:1Enroll%Patients% 4.1 1.2 1,5
Rewards:1Recognition% 3.2 1.3 1,5
Rewards:1Appreciation% 3.3 1.3 1,5
Physician)Characteristics)Included)in)Model
Age 52.6 9.8 34,82
Practice1Type
!!!Group!Practice 78%
%%%Hospital2Based 12%
!!!Solo!Practice 4%
!!Other/None!Listed 6%
Training1Location1
!!!U.S!Trained 80%
!!!Non!U.S!Trained 20%
Tenure1(Yrs.1In1Practice) 25.7 10.1 %8,%57
Medical1Specialty1
!!!Hematology!Oncology 40%
!!!Radiation!Oncology 21%
!!!Other!Specialty 18%
!!!Medical!Oncology 11%*
!!!Surgery! 10%*
Principal1Investigator1 9%
*Indicates%significant%difference%between%survey%respondents%and%nonOsurvey%respondents%
Other!race%includes%American%Indian,%Native%Hawaiian/Pacific%Islander,%More%than%one%race,%or%unknown
Radiation!Oncology%includes%diagnostic%radiology,%nuclear%medicine,%radiation%oncology,%radiology,%vascular%and%interventional%radiology
Other!specialist%includes%general%practice,%gynecological%oncology,%%pediatrics,%pediatric%hematology,%cardiovascular%disease%etc.%
Surgery%includes%colon%and%rectal%surgery,%critical%care%sugary,%general%surgery,%neurological%surgery,%surgical%oncology,%urological%surgery%etc.%
Hematology!oncology%includes%blood%banking,%hematology%oncology,%hematology
Descriptive)Variables
Outcome)
Perceptions)of))Implementation)Climate)
CCOP1Physician1Survey1Respondents1n=481
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 Mean%or%Proportion
%of%Sample% Standard%Deviation Range
Expectations:-Enroll%Patients
!!!Yes 35%
!!!No!! 65%
Support:-Identify%Patients 0.51 0.32 0,1.5
Support:-Enroll%Patients 0.50 0.32 0,1.5
Support:%Training
!!!Yes 32%
!!!No!! 68%
Rewards:-Recognition
!!!Yes 62%
!!!No!! 38%
Organizational+Factors+included+in+Model
Organizational-Maturity 25.5 6.2 8,30
Organizational-Size 14.3 15.6 2,87
Organizational-Structure
!!!Cancer!Center! 41%
!!!Research!Institution 24%
!!!Separate!Organization 30%
!!!Other! 5%
CCOP-Administrator-Survey-Respondents-n=47
Organizational+Implementation+Context
Table 9: Descriptive Statistics CCOP Organizations 
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Total&Effect Direct&Effect& &Indirect&Effect
Perceptions+of+Implementation+Climate 0.285* 0.285* N/A
Organizational+Implementation+Policies+
and+Practices+(OIPP)
0.069* N/A 0.069*
Age &&<0.264* <0.179 <0.085
Hospital,Based^ <0.043 <0.066 0.023
Solo1Practice^ <0.001 0.034 <0.035
Non1U.S.1Trained <0.035 <0.011 <0.024
PI 0.356* 0.322* 0.034
Tenure 0.224 0.117 0.107
Hematologist1Oncology+ <0.097 <0.075 <0.022
Radiation1Oncology+ &&<0.162* <0.120 <0.042
Surgery+ <0.114 <0.077 <0.037
Other1Specialty+ &&<0.147* <0.120 <0.027
Organizational1Size 0.028* N/A 0.028*
Structure:1Hospital1Cancer1Center++11 0.047* N/A 0.047*
Structure:1Research1Institute++ 0.016* N/A 0.016*
Structure:1Other++ 0.024* N/A 0.024*
Organizational1Maturity1 0.000 N/A 0.000
Note:1Total1effects1is1the1sum1of1direct1and1indirect1effects
*Statistically1Significant1(p<0.05)
^Compared1to1Group1Practice
+Compared1to1General1Non,Specialized1Oncology
++Compared1to1Separate1Non,Profit1Structure
Table+9:+Standardized+Total,+Direct,+and+Indirect+Effects+Aim+3
Outcome:)Enrollment)in)NCI2Sponsored)Cancer)Clinical)Trials)in)2011
Model&Fit&Statistics:&CFI=0.933;&TLI=&0.918;&RMSEA=0.045;&SRMR=0.048
Note:1Indirect1effects1are1the1product1of1the1regression1coefficients1leading1to1the1outcome.1For1example1for1
OIPP,1OIPP1predicts1perceptions1and1perceptions1predicts1enrollment.11The1indirect1effect1and1subsequently1
the1total1effect1of1OIPP1on1enrollment1equals1the1product1of1the1two1regression1coefficients1(From1Figure13)1
0.243*0.285=0.069
T  10: Standardized Total, Direct, and Indire  Effects, Aim 3 
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Figure 8: The Impact of Implementation Climate on Physician Enrollment 
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CHAPTER 7: SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE, AND RESEARCH 
 
Summary of Findings  
 
 The objective of this dissertation was to examine physician characteristics and 
organizational contextual factors that predict CCOP physician enrollment of patients in 
cancer clinical trials. Overall, there were several key findings across all aims. First, 
physicians’ attitudes, values, and perceptions were strong predictors of enrollment. In 
Aim 1, our results demonstrated that physicians’ attitudes towards participating in 
CCOP were a key determinant of enrollment (β=0.13; p=0.04). In Aim 2 we showed that 
physicians’ perceptions of a climate that encourages implementation (β=0.29; p=0.01) 
and perceived fit between CCOP goals and physicians’ values (β=0.18; p<0.00) were 
both significant determinants of enrollment. We also found that including innovation-
values fit as a moderator between perceptions of implementation climate and enrollment 
significantly improved model fit and explained 3% of the total variation in enrollment, 
although it was on the border of being statistically significant (p=0.06). Lastly, in Aim 3, 
we also demonstrated that physicians’ perceptions of implementation climate were a 
significant direct determinant of enrollment (β=0.29; p<0.00). 
Second, regarding physician characteristics, we only found significant direct effects 
on enrollment. In Aim 2, we found that only status as the CCOP PI had a significant 
effect on enrollment (β=0.31; p<0.00). In Aims 1 and 3, we tested whether physician 
characteristics such as status as the CCOP PI, age, tenure, medical specialty, practice 
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type, and training location directly impacted enrollment and indirectly impacted 
enrollment operating through either attitudes towards participating in CCOP (Aim 1) or 
perceptions of implementation climate (Aim 3). In both aims we found significant effects 
on enrollment for: status as the CCOP PI (both aims: β=0.36; p<0.00), age (Aim 1: β=-
0.30; p<0.00; Aim 3: β=-0.26; p=0.03), and non-oncology specialists (Aim 1: β=-0.15; 
p=0.02; Aim 3: β=-0.15; p=0.03). In addition, we found significant effects for tenure in 
Aim 1 (β=0.25; p=0.01) and for radiological oncologists in Aim 3 (β=-0.16; p=0.03).  We 
found no significant direct or indirect effects across all three aims for training location 
(U.S. versus foreign trained), practice type (hospital or solo versus group), hematologist 
oncologists, or surgeons (compared to non-specialized generalist oncologists).  
Lastly, we achieved mixed results regarding the importance of organizational context 
on physician enrollment. In Aim 1, we used objective assessments of organizational 
context, such as trainings offered, support staff provided, incentives rewarded, and 
expectations instituted. Although we found that organizational context had a significant 
direct effect on enrollment (β=0.19; p=0.02), it did not significantly influence enrollment 
indirectly operating through physician attitudes (p=0.32). Therefore, we only observed 
direct effects of objective assessments of organizational context on enrollment. In Aim 
2, we incorporated organizational context through physicians’ perceptions. In this case, 
as discussed, physicians’ perceptions of implementation climate significantly impact 
enrollment. In Aim 3, we included both objective assessments of organizational context 
(i.e., IPP) and physicians’ perceptions of implementation climate. In this aim, we found 
that perceptions of organizational context mediated the relationship between IPP and 
enrollment. IPP had a significant indirect effect on enrollment operating through climate 
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perceptions (β=0.07; p=0.01). In this aim we also included organizational control 
measures such as organizational maturity, size, and structure. We tested to see if these 
organizational factors influenced organizational IPP, and ultimately enrollment operating 
through physician perceptions of implementation climate. We found that although 
organizational maturity had no indirect effect on enrollment (p=0.97), organizational size 
(i.e., number of locations) did have an indirect effect on enrollment (β=0.03; p=0.02). In 
addition, CCOPs that were cancer centers (β=0.05; p=0.02), research institutions 
(β=0.02; p=0.04), and had other types of structures (β=0.03; p=0.02) compared to 
separate non-profit organizations had higher enrollment through IPP and perceptions of 
climate. Implications of these findings are discussed in detail below.  
Policy and Practice Implications  
 
 Findings from this dissertation have important policy and clinical practice 
relevance. The CCOP Network is in the midst of undergoing significant changes. NCI is 
merging CCOP with components of the NCI Community Cancer Centers Program 
(NCCCP), to create one comprehensive network for cancer care delivery research, the 
NCI Community Oncology Research Program (NCORP) (NCI, 2013).  The goal of 
NCORP is to bring advanced cancer prevention, control, treatment, and imaging clinical 
trials, cancer care delivery research, and disparities studies to individuals within the 
community (NCI, 2013). Awards for the community sites will occur in 2014. Findings 
from this dissertation are relevant for current CCOP sites considering repositioning 
themselves to participate in NCORP. Given the requirement for NCORP sites to enroll a 
minimum of 80 patients per year, our results could be used to create policies or institute 
practices aimed at increasing enrollment. For example, in Aims 1 and 3 physicians’ 
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attitudes and values were strong predictors of performance. These findings highlight the 
importance of recruiting physicians who value participating in clinical trials, find 
participating in trials important, and feel they are able to do so. 
Our results also highlight the importance of a strong perceived implementation 
climate on physician enrollment of patients in clinical trials. Physicians who felt their 
organization was supportive, provided rewards, and instituted expectations enrolled 
more patients in clinical trials than physicians who did not view their organization as 
having a strong implementation climate. Therefore NCORP or other sites may want to 
focus their efforts on creating an environment that physicians perceive as supporting 
implementation. For example, there is no “magic” number regarding the number of 
support staff needed to help screen or enroll patients, rather physicians need to feel that 
they are supported and perceive that they get what they need to identify and enroll 
patients in clinical trials. 
Our findings from Aim 3 suggest that organizational IPP influence physician 
perceptions of their organization even if they do not influence physicians’ attitudes and 
values as seen in Aim 1. Therefore, administrators should not discount the importance 
of instituting polices and practices that encourage enrollment. For example, program 
administrators should consider providing support for physicians’ research activities, 
such as staff to help consent and enroll patients, incentives for enrollment goals (e.g., 
small tokens of appreciation, public acknowledgment), and trainings to learn about 
latest developments in research. Such strategies may not directly change physician 
attitudes, but evidence from Aims 1 and 3 demonstrate that a supportive organizational 
context can encourage active physician participation in recruiting patients and 
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encourage positive physicians’ perceptions of how well their organization supports 
implementation.  
Our results extend beyond physician enrollment of patients in cancer clinical 
trials to other innovations and evidence-based practices in healthcare that are 
implemented by individual physicians on a voluntary basis. The ACA will require both 
healthcare organizations and individual physicians to implement complex and innovative 
strategies to improve the quality, efficiency, and value of healthcare. Some of the ACA 
directed innovations as well as the use of novel therapies only require implementation 
by a single physician, not collective, coordinated implementation among multiple 
individuals in an organization. Our results indicate that managers looking to increase 
use of an innovation, especially among physicians, should consider instituting 
expectations for its use. In addition, our results showed that managers should focus on 
ensuring physicians feel that they are supported and perceive that they get what they 
need to effectively implement an innovation as perceptions of climate can be more 
important than having a certain number of staff available or offering trainings in terms of 
encouraging implementation. Under this new era of reform, healthcare organizations are 
going to need to continuously implement complex innovations. Unfortunately, however, 
the failure rates for implementing such complex innovations are high (Alexander & 
Hearld, 2011). The results from this dissertation indicate that not only do individual 
characteristics impact innovation implementation, but organizational contextual factors 
help determine successful and sustained implementation as well.  
Research and Theory Implications  
 
This dissertation also has important implications for research and extends the use of 
 116 
 
innovation implementation theories in healthcare. First, our research is novel in that it is 
the first study to examine physician characteristics, physicians’ attitudes, values, and 
perceptions, along with organizational factors to explain the significant individual 
variation that occurs among physicians enrolling patients in cancer clinical trials. Our 
research is important as it demonstrates the utility of Klein and Sorra’s (1996) theory of 
innovation implementation in explaining individual level implementation effectiveness. 
Specifically, Aims 2 and 3 suggest that the model can be adapted to explain individual 
implementation by including personal characteristics and key constructs (e.g., 
perceptions of implementation climate, innovation-values fit) assessed at the individual 
level as opposed to aggregate measures assessed at the organizational level.  This will 
help guide future research, given many innovations and evidence-based practices in 
healthcare are implemented by individual physicians on a voluntary basis rather than by 
practices or organizations. Our findings also extend the literature as the models used in 
these studies focus both on individual and organizational level determinants of 
implementation effectiveness. Despite several theories that predict innovation 
implementation or implementation effectiveness among individuals or organizations, 
little research has focused on understanding the cross-level relationship between 
individual- and organizational-determinants. Our results, however, highlight the 
importance of organizational context, personal characteristics, and individual attitudes, 
values, and perceptions in predicting implementation effectiveness at the individual 
level.  
We were also able to extend the current literature by quantitatively testing the theory 
of innovation implementation (Klein & Sorra, 1996) in a healthcare setting. It is often 
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difficult to test this theory quantitatively given the large sample of participants and 
organizations required. Although the model has been discussed within health services 
before, the studies have been predominately qualitative in nature (Weiner et al., 2011; 
Weiner, Haynes-Maslow, Campbell, Kahwati, & Kinsinger, 2012; Teal, Bergmire, 
Johnston, & Weiner, 2012; Weiner, Lewis, & Linnan, 2009; Helfrich et al., 2007).  
Although important, qualitative studies tend to utilize smaller sample sizes, have limited 
external generalizability, and present challenges in standardizing the measurement of 
key constructs. Our analysis, however, tested the framework with greater precision, 
which allows researchers to compare results across settings, samples, and innovations.  
 Our studies advance the use of the theory of innovation implementation in 
healthcare (Klein & Sorra, 1996) as we empirically examined whether innovation-values 
fit moderates the effect of perceptions of implementation climate on implementation 
effectiveness. Prior research testing the theory has included both concepts in their 
research, but our study is the first to examine the proposed moderated relationship 
between innovation-values fit, implementation climate, and implementation 
effectiveness (Holahan et al., 2004) (Dong et al., 2008) (Klein et al., 2001) (Osei-Bryson 
et al., 2008). Although including innovation-values fit as a moderator improved model fit 
and explained 3% of the overall variation in implementation effectiveness, it approaches 
significance (p=0.06). Explaining 3% of the overall variance, however, is noteworthy as 
moderator effects are notoriously difficult to detect (Evans, 1985) (Champoux, 1987). 
This model should be tested in additional settings to ensure its generalizability in other 
healthcare contexts.  
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Lastly, our results can be used in conjunction with other innovation theories and 
frameworks. For example, the Consolidated Framework for Implementation Research 
(CFIR) offers guidance as to the possible relevant predictors of implementation 
effectiveness, such as intervention characteristics, factors at the system and 
organizational levels, and characteristics of the individuals implementing the innovation 
(Damschroder et al., 2009). The CFIR does not, however, provide rationale as to why 
some of the domains may be more relevant than others and how they are related in 
certain circumstances. Therefore our results could be useful in selecting relevant 
constructs from the CFIR to examine implementation effectiveness of individually driven 
innovations in a healthcare setting. For example in Aim 3, as part of the inner setting or 
organizational level construct, the CFIR includes organizational characteristics, such as 
size and structure, which we found to be important determinants of organizational IPP. 
The inner setting also includes policies and practices related to implementation climate, 
such as organizational incentives and rewards, clearly communicated goals and 
feedback, available resources, and access to information through trainings, all of which 
were included in our model as IPP and/or in physicians’ perceptions of implementation 
climate. Lastly, the CFIR also includes characteristics of the individual such as tenure, 
age, and experience. Our research indicates how these constructs not only relate to one 
another, but how they also impact implementation effectiveness.  
Limitations  
 
There were several limitations associated with these studies. First, we only 
included physicians who participated in CCOP and completed the 2011 CCOP 
Physician Survey.  Therefore, our findings suggest the organizational factors and 
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individual physician characteristics that are most relevant to encourage active 
participation in CCOP or other volunteer research programs. It is important to note, 
however, that many organizational strategies (e.g., recognition of high achievers, 
expectations for enrollment) could be implemented by diverse organizations to increase 
physician participation in clinical research or increase physician adoption of voluntary 
based innovations. Second, our study is cross-sectional and represents a single point in 
time. Future studies should consider examining implementation climate over the course 
of implementation to better understand how climate may vary over time or among 
different groups within a single organization. We also lacked the data to incorporate 
patient characteristics in the analyses. Ultimately patients are the final decision makers 
regarding their participation in a cancer clinical trial. We were unable to distinguish 
physicians failing to offer a cancer clinical trial from patients’ refusal to enroll. However, 
given that 75% of patients agree to enroll if offered (Albrecht et al., 2008) we do not 
believe this to be a significant limitation.  Lastly, we were also limited in the data 
available to examine individual physician enrollment within each of the models. Given 
we were only able to explain 21%, 38%, and 24% of the variance in enrollment in Aims 
1, 2, and 3 respectively, there are clearly other relevant factors of implementation 
effectiveness that we were not able to capture in this analysis. Also given data 
constraints we were not able to examine some of the other model constructs proposed 
by Klein and Sorra (1996) (e.g., innovation effectiveness, strategic accuracy of 
innovation adoption) to understand their role in explaining implementation effectiveness. 
Future Directions  
 
This dissertation provides the foundation for several future studies. In this 
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dissertation we were interested in explaining variation in enrollment among individual 
physicians (i.e., implementation effectiveness), thus we tested the models at the 
individual level. The models are proposed, however, at the organizational level and 
should also be tested with the intended unit of analysis. Although the intraclass 
correlations are modest, due to low between group variance, the relatively high 
interrater agreement statistics indicate that there is likely enough within group 
agreement to aggregate many of the variables to the CCOP level (Table 3).  Therefore 
the models tested in Aims 2 and 3 should be examined at the organizational level within 
a health services setting.  We could explore this further using a cross-level moderation 
test in multilevel modeling.  
 In addition, these studies should also be replicated in other health services 
settings implementing other innovations. In Aim 1, we found that physicians’ attitudes 
and values was not a significant mediator between organizational context and 
enrollment. Similarly in Aim 2, we found that innovation-values fit was not a significant 
moderator between physicians’ perceptions of implementation climate and enrollment. 
Future work should explore these proposed relationships further given that attitudes 
may be a significant mediator or innovation-values fit a significant moderator in contexts 
where innovation implementation is mandatory and there is more variation in attitudes 
and in the perceptions regarding innovation-values fit or implementation climate. For 
example, if physicians are forced to adopt an innovation, those that feel that the 
innovation aligns with their values may be more likely to adopt and use the innovation, 
regardless of climate. A strong sense of innovation-values fit would also likely 
strengthen their perceptions of their organization’s implementation climate as they are 
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enthusiastic about the innovation and are committed to using it. If innovation-values fit is 
weak and users are forced to implement an innovation, they are likely unenthusiastic 
and unwilling to implement regardless of the organization offering incentives to adopt. 
Conclusion  
 
 The goal of this dissertation was to examine the individual characteristics and 
organizational contextual factors that determine patient enrollment in cancer clinical 
trials among CCOP physicians. This was accomplished through three aims that 
explored the ways organizational context can be incorporated into research. The first 
aim used objective assessments of organizational context, the second aim used 
physicians’ perceptions of context, and the third aim included both objective 
assessments of organizational context and physicians’ perceptions.  Overall, we found 
that physician characteristics, such as status as the CCOP PI and age, physicians’ 
attitudes, values, and perceptions regarding climate, and organizational policies and 
practices determined enrollment. Our results can not only be used in the formation of 
new NCORP policies and in clinical practice to increase physician participation in 
voluntary based innovations, but they can also be used in research as we extended the 
boundaries in which innovation implementation frameworks can be used. We 
demonstrated the utility of these models to explain individual innovation implementation 
in a health services setting.  
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APPENDIX   
 
Aim 2: : Interaction Between Implementation Climate and Innovation-Values Fit using 
Linear Regression  
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